



# Leelanau County Government Center

Leelanau County Land Bank Authority (LC-LBA)

Website: <http://www.leelanau.gov/landbank.asp>

8527 E. Government Center Dr.  
Suttons Bay MI 49682 231-256-9838

---

## NOTICE OF MEETING

A Special Session of The Leelanau County Land Bank Authority (LC-LBA) will meet **On Tuesday May 7th,**

**2024 at 9:00 am**

**at the**

**Leelanau County Government Center**

## DRAFT AGENDA

**PLEASE TURN OFF ALL CELL PHONES**

**CALL TO ORDER**

**PLEDGE OF ALLEGIANCE**

**ROLL CALL**

**APPROVAL OF AGENDA**

**PUBLIC COMMENT**

### **PURPOSE OF THE MEETING – DISCUSSION/POTENTIAL ACTION:**

1. High Street Demolition
  - a. Reviewal of Bids *pgs. 2-4*
  - b. Contractor Selection
2. Board Member Vacancy *pgs. 5-47*

**PUBLIC COMMENT**

**MEMBER COMMENTS**

**CHAIRPERSON COMMENTS**

**ADJOURN**

### **Members**

John A. Gallagher III – Chair  
Dan Heinz – Vice Chair  
Gail Myer-- Secretary  
Rick Foster -- Treasurer  
Gwenne Allgaier  
Richard Lewis  
Vacancy

Bid Tabulation Sheet  
Demolition of Commercial Property  
Former Leelanau Memorial Hospital  
201 S. High St.  
Northport, MI 49670

Bid Release Date: 4/10/24  
Bid Due Date: 4/29/24

Qualified Elements Submitted - X=received, comments if needed

Contractor Name	Bid form with completed questions	Bondability Letter	Non-Iran Form	COI	Violations w/in 3 years	Qualifications	Prior Experience	Subcontractors	References	Additional Info/Comments
Dore & Associates, Inc	x	x	x	x	listed "No" - 2024 open non serious abatement fine; 2023 citation deleted, 2021 multiple serious fines - resolved	x	x-13 pages	None	13 pages of references provided	bid bond submitted (not a requirement of the RFP), provided extensive equipment list
Pitsch Companies	x	x	x	x - current policy expiring soon	Yes, asbestos related - dismissed, resolved, or settled (search found 2021 citations listed as "serious" resolved)	x	x- 66 years	None	Julie Tresedder, Trimedia EE, 906-228-5125, jtresedder@trimediaee.com; Allegan County and Pioneer Construction	demo, asbestos, and lead abatement licenses. Also certified in HAZWOPER, First Aid, AED training, asbestos-lead-silica dust awareness and OSHA safety.
Bay Area Demolition	x	x	x	x	Listed "No" - 2024 abatement citation, no fine - resolved	x	x-3 years (50 structures/yr)	Mid State Asbestos Abatement	Tom Darga, Darga Works 231-944-2777; E&L Construction and Cunningham Limp	Builders license and State of MI Asbestos Abatement license
Walton Contracting	x	x	x	x	listed "No" - 2022 "serious" construction fines issued resolved	did not provide much detail on qualifications	x- 5 years	GFL	Comstock Construction 231-946-4911; RCI Construction and Hallmark Construction	commercial excavator contractor - TC based, certifications left blank
Adamo Contracting Co.	x	x	x	x	listed "No" - name variation with same mailing address 2021 citation deleted	x	x- 60 years	Rightway Remediation	Donna Rice, Detroit Building Authority, 313-224-4599, riced@detroitmi.gov; Wayne County Airport Authority and	State asbestos licensing, OSHA 30, MUST drug program and training modules
Bierlein Companies, Inc	x	x	submitted with printed company name/date but unsigned	x	none in 2021 or 2022, 2023 had "other than serious" asbestos related citation resolved during state inspection	x	x-67 years	None	Corey Barr, City Manager City of Manistique, 906-341-2290, City of Midland and St. Ignace Area Schools	too many certifications to list included in resumes, abatement license and M& A license submitted, also included EMR safety ratings for last 5 years and all are below 1 (desired)
Bolle Contracting, LLC	x	x	x	x	several minor violations - all resolved	x	x-20 years	None	20+ project examples listed, most with references	builders license, asbestos abatement license
Smalley Construction, Inc	x	x	x	x	2024-open inspection (does not indicate a citation will be issued), 2020 minor - cadmium dust citation no plan onsite resolved	x	x-48 years	None	Therese Searles, Christopher Kestner Materials Testing Consultants, Inc. 616-608-1540, ckestner@mtc-test.com, Wayne County LBA and more	asbestos abatement license, lead safety trained, HAZWOPER trained, maintaining "no injury" accident report, Safety Plan available upon request
Elmer's Crane & Dozer, Inc	x	x	x	x	Listed "No" -2023 citation w/o fine, 2022 silica violation with fine resolved	x	x- 68 years	Apple Fence Co. (fencing) Mis State Asbestos Removal (abatement)	City of Traverse City, info@downtowntc.com, 231-922-2050; Hallmark Construction and Socks Construction	spent the most time physically onsite during the bid walkthrough, builders license

Bid Tabulation Sheet  
Demolition of Commercial Property  
Former Leelanau Memorial Hospital  
201 S. High St.  
Northport, MI 49670

Bid Release Date: 4/10/24  
Bid Due Date: 4/29/24

Organized Lowest to Highest Total Bid (9 bids received)

Contractor Company Name Address	Main Contact Name Email Address/Phone Number	Asbestos Abatement and Universal Waste Removal	Demolition	Site Restoration	Bonds	Total Base Bid	Estimated Start (in # of days)	Length of time to complete job (in # of days)	Total Time (in # of days)	Fully Responsive Bid? Y or N	Additional Info
Dore & Associates, Inc. PO Box 338 Washington Ave Bay City, MI 48707	Jason C. Dore est@doreassoc.com 989-684-8411	\$60,700	\$184,200	\$29,400	\$5,400	<b>\$279,700</b>	30	120	150	Y*	timing beyond grant period
Pitsch Companies 675 Richmond St NW Grand Rapids, MI 49504	Eugene Gutting gene@pitschco.com (616) 363-4895	\$33,000	\$220,000	\$85,000	\$5,000	<b>\$343,000</b>	15	75	90	Y	
Bay Area Demolition 18657 Honor Hwy. Interlochen, MI 49643	Kristopher Wood bayareademopros@gmail.com 231-709-5895	\$85,000	\$190,000	\$100,000	\$11,250	<b>\$386,250</b>	28	35	63	Y	
Walton Contracting 526 W. 14th St, 209 Traverse City, MI 49684	Dustin Schroeder dustin@waltoncontracting.net 231-883-8020	\$169,673 <i>(illegible)</i>	\$258,550.00	\$51,500.00	\$9,500.00	<b>\$481,223</b> <i>(handwritten, not sum)</i>	45	35	80	Y	abatement bid is illegible - the third number could be a 1, 7, or 9 but the total bid is more than the sum of the highest value
Adamo Demolition Co. 320 E 7 Mile Rd Detroit, MI 48203	Richard M Adamo 313-892-7330	\$149,710.00	\$247,725.00	\$110,190.00	\$4,495.00	<b>\$512,120</b>	21	58	79	Y	
Bierlein Companies, Inc 2000 Bay City Road Midland, MI 48642	Patrick Wurtzel mwwood@bierlein.com 989-698-2294	\$55,000.00	\$400,000	\$160,000	\$9,500	<b>\$624,500</b>	35 (working)	25 (working)	60 (working)	Y*	costs do not include removing asphalt stone base, removing storm drains or "chasing" underground utilities, or managing any found vermiculite
Bolle Contracting, LLC 408 E 4th Street Clare, MI 48617	Mark Bolle mark@bollecontracting.com 989-386-7311	\$65,000.00	\$499,600	\$50,000	\$6,000	<b>\$620,600.00</b>	20	40	60	Y	
Smalley Construction, Inc. 1224 Locust St Jackson, MI 49203	Sue A. Smalley sue@smalleyco.com 844-757-3366	\$85,000.00	\$450,000	\$122,360	\$6,640	<b>\$664,000.00</b>	15	150	165	Y*	timing beyond grant period
Elmer's Crane and Dozer, Inc. 3600 Rennie School Rd Traverse City, MI 49685	Sam Cope contracts@teamelmers.com 231-943-3443	\$88,211.06	\$655,037.45	\$207,316.07	\$3,399.09	<b>\$953,963.67</b>	30	50	80	Y	

\*Bids were considered responsive if all requested materials were satisfactorily submitted. Small clarifications needed do not constitute non-responsiveness. Project timing is considered a potentially negotiable item. However, at the discretion of the Board, timing beyond the grant period could be a consideration for disqualification.

Bid Tabulation Sheet  
Demolition of Commercial Property  
Former Leelanau Memorial Hospital  
201 S. High St.  
Northport, MI 49670

Bid Release Date: 4/10/24  
Bid Due Date: 4/29/24

Organized Lowest to Highest Total Bid (9 bids received)

<b>Contractor Company Name Address</b>	<b>Total Base Bid</b>	<b>Fully Responsive Bid? Y or N</b>
Dore & Associates, Inc. PO Box 338 Washington Ave Bay City, MI 48707	\$279,700.00	Y*
Pitsch Companies 675 Richmond St NW Grand Rapids, MI 49504	\$343,000.00	Y
Bay Area Demolition 18657 Honor Hwy. Interlochen, MI 49643	\$386,250.00	Y
Walton Contracting 526 W. 14th St, 209 Traverse City, MI 49684	\$481,223.00	Y
Adamo Demolition Co. 320 E 7 Mile Rd Detroit, MI 48203	\$512,120.00	Y
Bierlein Companies, Inc 2000 Bay City Road Midland, MI 48642	\$624,500.00	Y*
Bolle Contracting, LLC 408 E 4th Street Clare, MI 48617	\$620,600.00	Y
Smalley Construction 1224 Locust St Jackson, MI 49203	\$644,000.00	Y*
Elmer's Crane & Dozer, Inc. 3600 Rennie School Rd, Traverse City, MI 49685	\$953,964.00	Y

\*Bids were considered responsive if all requested materials were satisfactorily submitted. Small clarifications needed do not constitute non-responsiveness. Project timing is considered a potentially negotiable item. However, at the discretion of the Board, timing beyond the grant period could be a consideration for disqualification.

## Leelanau County Appointment Application to Boards/Commissions/Committees/Authorities

The Leelanau County Board of Commissioners is committed to seeking qualified and interested citizens to participate in public service through appointment to various Boards/Commissions/Committees/Authorities. To be considered for an appointment, a citizen must be a resident of Leelanau County, a registered voter of Leelanau County, and must have an application on file in the Administrator's Office. Applications will expire four (4) years from the issue date.

**Please type or print legibly**

Name: LoisBahle	Date: 11/9/22
Address: PO Box 221, Suttons Bay, Mi 49682	
Occupation: Retired	
Daytime Telephone: 231-866-1466	
Email Address: loisbahle@gmail.com	

1. Are you a resident of Leelanau County?       Yes       No
2. Are you a registered voter of Leelanau County?  Yes       No

Township or Village: Suttons Bay Village

3. Can you regularly attend scheduled meetings?    Day:     Yes     No  
                                                                                  Evening:  Yes     No

4. State your understanding of citizen involvement on Leelanau County Boards, Commissions, Committees, and Authorities (use page 4 if you need additional space).  
I currently serve on the Housing Action Committee, SWC, Land Bank and Brownfield Authority

5. What are your qualifications for appointment?  
Past experience on the Village planning Commission, County Planning Commission, original Leelanau General Plan and volunteer for many non profits.

6. Please indicate below with an X any/all Boards/Commissions/Committees/Authorities you are willing to serve on. Please place two Xs on the one(s) you feel strongly about:

	X	Board/Commission/Committee/Authority	Have you served on this board in the past? Give dates.
1		<b>Area Agency on Aging of Northwest Michigan (AAA)</b> (1 member / 2 year terms)	
2		<b>Bay Area Transportation Authority (BATA)</b> (2 members / 3 year terms)	
3		<b>Benzie-Leelanau District Health Department Board of Health</b> (3 members / 2 year terms)	
4		<b>Benzie-Leelanau Environmental Health Board of Appeals</b> (3 members / 2 year terms)	
5		<b>Brownfield Redevelopment Authority (BRA)</b> (7 members / 3 year terms)	X
6		<b>Construction Codes Authority Board of Appeals</b> (5 members / 5 year terms) <i>Specify the category(ies) AND list your qualifications under question #5: Select One</i>	
7		<b>Michigan Department of Health and Human Services (DHHS)</b> (2 members / 3 year terms) See Agency-specific application	
8		<b>Land Bank Fast Track Authority (LBA)</b> (7 members / 3 year terms)	X
9		<b>Northern Lakes Community Mental Health Authority (CMH)</b> (2 members / 3 year terms)	
10		<b>Northern MI Regional Entity (NMRE) Substance Use Disorder Services Policy Oversight Board</b> (1 member / 3 year term)	
11		<b>Northwest Michigan Community Action Agency (NMCAA)</b> (1 member / 3 year term - <b>COMMISSIONER APPOINTMENT</b> )	
12		<b>Northwestern Regional Airport Commission (NRAC)</b> (2 members / 3 year terms)	
13		<b>Parks &amp; Recreation Commission (P &amp; R)</b> (10 members / 3 year terms)	
14		<b>Planning Commission (PC)</b> (11 members / 3 year terms) <i>Specify category(ies) you qualify for AND list your qualifications for each category under question #5: Select One</i>	
15		<b>Soil Erosion, Sedimentation and Stormwater Runoff Control Ordinance Board of Appeals (SESSRC)</b> (5 members / 3 year terms)	
16		<b>Solid Waste Council (SWC)</b> (14 members / 2 year terms) <i>Specify category(ies) you qualify for AND list your qualifications under question #5: Select One</i>	X
17		<b>Veterans Affairs Administrative Committee (VA)</b> (1 member / 2 year term - must be a Veteran)	
18		<b>Workforce Development Board (WDB)</b> (2 members / 2 year terms) <i>Must apply with Agency specific application only</i>	

7. List references and contact information (minimum of two):

Reference #1  
Trudy Galla

Reference #2  
Ty Wessell

8. Are you available to attend an Open Meetings Act Training Session and a Freedom of Information Act Training Session during your first year of appointment?

Yes  No

9. Are you willing to consent to a Background Investigation?

Yes  No

10. Signature:

 \_\_\_\_\_

Leelanau County  
Appointment Application to Boards/Commissions/Committees/Authorities

The Leelanau County Board of Commissioners is committed to seeking qualified and interested citizens to participate in public service through appointment to various Boards/Commissions/Committees/Authorities. To be considered for an appointment, a citizen must be a resident of Leelanau County, a registered voter of Leelanau County, and must have an application on file in the Administrator's Office. Applications will expire four (4) years from the issue date.

Please type or print legibly

Name:	Melvin L Black	Date:	10-25-22
Address:	13846 S. Cedar Run Rd		
Occupation:	Retired - still Licensed broker		
Daytime Telephone:	231-578-0581		
Email Address:	Bwellmel46@gmail.com - (all Lower case)		

- 1. Are you a resident of Leelanau County?  Yes  No
- 2. Are you a registered voter of Leelanau County?  Yes  No

Township or Village: Select One Solen

- 3. Can you regularly attend scheduled meetings? Day:  Yes  No  
Evening:  Yes  No

4. State your understanding of citizen involvement on Leelanau County Boards, Commissions, Committees, and Authorities (use page 4 if you need additional space). *consider each issue and vote for what is best for residents of Leelanau County*

5. What are your qualifications for appointment? *Current Lic, Broker served on several board and committees over last several years (see resumé)*



6. Please indicate below with an X any/all Boards/Commissions/Committees/Authorities you are willing to serve on. Please place two Xs on the one(s) you feel strongly about:

	X	Board/Commission/Committee/Authority	Have you served on this board in the past? Give dates.
1		<b>Area Agency on Aging of Northwest Michigan (AAA)</b> (1 member / 2 year terms)	
2		<b>Bay Area Transportation Authority (BATA)</b> (2 members / 3 year terms)	
3		<b>Benzie-Leelanau District Health Department Board of Health</b> (3 members / 2 year terms)	
4		<b>Benzie-Leelanau Environmental Health Board of Appeals</b> (3 members / 2 year terms)	No
5	X	<b>Brownfield Redevelopment Authority (BRA)</b> (7 members / 3 year terms)	
6		<b>Construction Codes Authority Board of Appeals</b> (5 members / 5 year terms) <u>Specify the category(ies) AND list your qualifications under question #5:</u> Select One	
7		<b>Michigan Department of Health and Human Services (DHHS)</b> (2 members / 3 year terms) See Agency-specific application	
8	X	<b>Land Bank Fast Track Authority (LBA)</b> (7 members / 3 year terms)	No Lic Broker
9		<b>Northern Lakes Community Mental Health Authority (CMH)</b> (2 members / 3 year terms)	
10		<b>Northern MI Regional Entity (NMRE) Substance Use Disorder Services Policy Oversight Board</b> (1 member / 3 year term)	
11		<b>Northwest Michigan Community Action Agency (NMCAA)</b> (1 member / 3 year term - <b>COMMISSIONER APPOINTMENT</b> )	
12		<b>Northwestern Regional Airport Commission (NRAC)</b> (2 members / 3 year terms)	
13		<b>Parks &amp; Recreation Commission (P &amp; R)</b> (10 members / 3 year terms)	
14		<b>Planning Commission (PC)</b> (11 members / 3 year terms) <u>Specify category(ies) you qualify for AND list your qualifications for each category under question #5:</u> Select One	
15		<b>Soil Erosion, Sedimentation and Stormwater Runoff Control Ordinance Board of Appeals (SESSRC)</b> (5 members / 3 year terms)	
16		<b>Solid Waste Council (SWC)</b> (14 members / 2 year terms) <u>Specify category(ies) you qualify for AND list your qualifications under question #5:</u> Select One	
17		<b>Veterans Affairs Administrative Committee (VA)</b> (1 member / 2 year term - must be a Veteran)	
18		<b>Workforce Development Board (WDB)</b> (2 members / 2 year terms) <u>Must apply with Agency specific application only</u>	

7. List references and contact information (minimum of two):

Reference #1

Ken Hulka managing Director  
Muskegon County Road Comm.  
231-740-9047

Reference #2

Bill Carlson  
OWNER Nexes Realty WAS AN ASSOC.  
231-739-3501 BROKER AT NEXES

8. Are you available to attend an Open Meetings Act Training Session and a Freedom of Information Act Training Session during your first year of appointment?

Yes  No

9. Are you willing to consent to a Background Investigation?

Yes  No

10. Signature:

Melvin L. Black

# Melvin Black

Resume for Road Vacant Road Commission Position

13846 S. Cedar Run Rd  
Traverse City, MI 49684  
(231)578-0581  
swellmel46@gmail.com

## CIVIL EXPERIENCE

### **Muskegon County Road Commission, Muskegon, MI** — Board Member

2009 - OCTOBER 2019

2016-2019 CHAIRMAN

Gained valuable knowledge through numerous state wide seminars.  
Well connected throughout the state and industry  
Experience leading in a professional manner

### **Leelanau County Planning Board, Lake Leelanau, MI** — Board Member

May 2020 - Present

Dealing with future plans for Leelanau County

## JOB HISTORY

### **The Muskegon Chronicle, Muskegon, MI — Stereotyper**

June 1968 - June 1972

Printing plate maker and ad builder

### **The Muskegon Chronicle, Muskegon, MI — District Circulation Manager**

June 1972 - January 1980

Carrier supervision

### **Construction, Muskegon MI — Self Employed Contractor**

February 1980 - June 1983

Remodeling and Building

### **Atlas Trucking, Muskegon, MI — Lease Account Manager**

June 1983 - November 1989 after Atlas sold to Ryder Trucking

Leased Commercial Trucks from Holland to Mackinaw

## SKILLS

Experienced Speaker

Leadership

Negotiating

Budgeting

Strong Interpersonal Skills

## AWARDS

Muskegon County Road  
Commission Outstanding  
Chairman

15 Year Award, Muskegon  
County Prison Ministry  
Volunteer Chaplin

## VOLUNTEER ACTIVITIES

### JUNIOR ACHIEVEMENT

6 Year teaching civics to  
2nd-4th graders

### CRIMINAL ADVISORY BOARD

2 years working with 2  
Muskegon judges, a sheriff, 2  
chief of police, 2 state parole  
board members & 2  
community mental health  
professionals to find  
alternative punishment for  
nonviolent criminals

### AMERICAN RED CROSS

16 gallons of blood donated

**R & S Truck Leasing, Muskegon, MI — Vice President of Sales**

February 1990 - March 1992 Company Closed

Leased & Purchased Trucks

**Star Truck Rental & Leasing, Muskegon, MI — Lease Account Manager**

June 1991 - March 1996 due to downsizing

Opened the Western Michigan Market for Star Trucking

**CTI Trailer Leasing, Grand Rapids, MI — Lease Account Manager**

April 1996-March 2000 Business Bankruptcy

Leasing Fleet of trailers over a three state region

**Nexes Realty, Muskegon, MI — Realtor/Associate Broker**

April 2000 -December 2018 Retirement

Listed and sold residential and commercial real estate

**W MICHIGAN TRAFFIC CLUB**

President 4 years

Treasurer 4 years

**North Michigan District of the Wesleyan Church**

3 years on the board

managing 57 churches

**BIG BROTHERS, BIG SISTERS**

3 years in mentorship

**EDUCATION**

**Greenville High School, Greenville MI - HS Diploma**

1965

**Muskegon Community College, Muskegon, MI**

1972-1986

128 Credit Hours in Business Administration & Traffic Management

3.67 gpa

**PERSONAL**

**Married to Joyce Black — 52 years**

**Raised 4 Children— Rob 57, Leanne 49, Tim 48 & Dan 45**

**16 Grandchildren**

### Leelanau County Appointment Application to Boards/Commissions/Committees/Authorities

The Leelanau County Board of Commissioners is committed to seeking qualified and interested citizens to participate in public service through appointment to various Boards/Commissions/Committees/Authorities. To be considered for an appointment, a citizen must be a resident of Leelanau County, a registered voter of Leelanau County, and must have an application on file in the Administrator's Office. Applications will expire four (4) years from the issue date.

Please type or print legibly

Name: Rodney M Brush	Date: 08/12/2021
Address: 320 N Hoeft Rd, Lake Leelanau, MI 49653	
Occupation: Partially retired, business development, realtor.	
Daytime Telephone: 231-499-6334	
Email Address: Rodney.Brush@CBGreatLakes.com	

1. Are you a resident of Leelanau County?  Yes  No

2. Are you a registered voter of Leelanau County?  Yes  No

Township or Village: Leland Township

3. Can you regularly attend scheduled meetings? Day:  Yes  No  
Evening:  Yes  No

**RECEIVED**  
**AUG 13 2021**  
**LEELANAU COUNTY**  
**ADMINISTRATOR**

4. State your understanding of citizen involvement on Leelanau County Boards, Commissions, Committees, and Authorities (use page 4 if you need additional space).

Citizens are used to look at options, gather data, and make recommendations for any given situation the board may be considering. They should have the communities greater good and well being as their first priority. Board members should act as advisors.

5. What are your qualifications for appointment?

I have sat on, and led multiple boards in the past. Community, state wide, government, and business boards which some were volunteer, and some were paid. I have a college degree in finance/economics from Hope College. For 30 years, I started and was president of 3 corporations with multiple locations in the greater Grand Rapids area. All were sold in 2018. During those years, I was able to work with multiple local communities and their governments. For those 30 yrs, my wife and I summered here in Leelanau county. We have been here full time since 2018.

Since then, I have volunteered for local community events, like Un Caged, and Adopt-a-Road. I currently am a state licensed Realtor, and I'm willing to serve where I could be of help.

See Attachment #1 Page 4

6. Please indicate below with an X any/all Boards/Commissions/Committees/Authorities you are willing to serve on. Please place two Xs on the one(s) you feel strongly about:

	X	Board/Commission/Committee/Authority	Have you served on this board in the past? Give dates.
1		<b>Area Agency on Aging of Northwest Michigan (AAA)</b> (1 member / 2 year terms)	
2		<b>Bay Area Transportation Authority (BATA)</b> (2 members / 3 year terms)	
3		<b>Benzie-Leelanau District Health Department Board of Health</b> (3 members / 2 year terms)	
4		<b>Benzie-Leelanau Environmental Health Board of Appeals</b> (3 members / 2 year terms)	
5	X	<b>Brownfield Redevelopment Authority (BRA)</b> (7 members / 3 year terms)	NO
6		<b>Construction Codes Authority Board of Appeals</b> (5 members / 5 year terms) <i>Specify the category(ies) AND list your qualifications under question #5: Select One</i>	
7		<b>Michigan Department of Health and Human Services (DHHS)</b> (2 members / 3 year terms) <i>See Agency-specific application</i>	
8	X	<b>Land Bank Fast Track Authority (LBA)</b> (7 members / 3 year terms)	NO
9		<b>Northern Lakes Community Mental Health Authority (CMH)</b> (2 members / 3 year terms)	
10		<b>Northern MI Regional Entity (NMRE) Substance Use Disorder Services Policy Oversight Board</b> (1 member / 3 year term)	
11		<b>Northwest Michigan Community Action Agency (NMCAA)</b> (1 member / 3 year term - <b>COMMISSIONER APPOINTMENT</b> )	
12		<b>Northwestern Regional Airport Commission (NRAC)</b> (2 members / 3 year terms)	
13		<b>Parks &amp; Recreation Commission (P &amp; R)</b> (10 members / 3 year terms)	
14	XX	<b>Planning Commission (PC)</b> (11 members / 3 year terms) <i>Specify category(ies) you qualify for AND list your qualifications for each category under question #5: Legal/Real Estate</i> <input checked="" type="checkbox"/>	NO
15		<b>Soil Erosion, Sedimentation and Stormwater Runoff Control Ordinance Board of Appeals (SESSRC)</b> (5 members / 3 year terms)	
16		<b>Solid Waste Council (SWC)</b> (14 members / 2 year terms) <i>Specify category(ies) you qualify for AND list your qualifications under question #5: Select One</i>	
17		<b>Veterans Affairs Administrative Committee (VA)</b> (1 member / 2 year term - must be a Veteran)	
18		<b>Workforce Development Board (WDB)</b> (2 members / 2 year terms) <i>Must apply with Agency specific application only</i>	

7. List references and contact information (minimum of two):

Reference #1  
Elizabeth Schaub  
PO Box 426  
Suttons Bay, MI 49682  
231-360-1100


Reference #2  
Dennis Pool  
2086 Pleasant Pond  
Byron Center, MI 49315  
616-540-5400

8. Are you available to attend an Open Meetings Act Training Session and a Freedom of Information Act Training Session during your first year of appointment?

Yes  No

9. Are you willing to consent to a Background Investigation?

Yes  No



10. Signature: Rodney M Brush Rodney M Brush  
2021.08.12 14:49:34 -04'00'

## Leelanau County Appointment Application to Boards/Commissions/Committees/Authorities

The Leelanau County Board of Commissioners is committed to seeking qualified and interested citizens to participate in public service through appointment to various Boards/Commissions/Committees/Authorities. To be considered for an appointment, a citizen must be a resident of Leelanau County, a registered voter of Leelanau County, and must have an application on file in the Administrator’s Office. Applications will expire four (4) years from the issue date.

**Please type or print legibly**

Name: Barbara A. Conley MD	Date: 07/12/2022
Address: PO BOX 178, 505 N. Mill St., Northport, MI 49670	
Occupation: physician, retired	
Daytime Telephone: 231-632-0453	
Email Address: tel124now@aol.com	

1. Are you a resident of Leelanau County?  Yes  No

2. Are you a registered voter of Leelanau County?  Yes  No

Township or Village: Leelanau Township

3. Can you regularly attend scheduled meetings? Day:  Yes  No  
Evening:  Yes  No

4. State your understanding of citizen involvement on Leelanau County Boards, Commissions, Committees, and Authorities (use page 4 if you need additional space).  
To oversee and provide input into the policies of the Board, review and approve expenses and budgets and to bring expertise and issues forward to help improve service to the public

5. What are your qualifications for appointment?  
Currently licensed to practice medicine  
Current Chair, Benzie-Leelanau District Health Dept Board of Health  
Served on the Benzie-Leelanau District Board of Health since January 2019  
Volunteer as contact tracer and vaccine administrator  
other board service - current vice president Northport Public School Board of Education  
Previous board service - Friends School Baltimore, American Cancer Society, Institutional Review Boards at University of Maryland and the National Cancer Institute  
Other: Contract officer for National Cancer Institute until about 2016



6. Please indicate below with an X any/all Boards/Commissions/Committees/Authorities you are willing to serve on. Please place two Xs on the one(s) you feel strongly about:

	X	Board/Commission/Committee/Authority	Have you served on this board in the past? Give dates.
1		<b>Area Agency on Aging of Northwest Michigan (AAA)</b> (1 member / 2 year terms)	
2		<b>Bay Area Transportation Authority (BATA)</b> (2 members / 3 year terms)	
3	X	<b>Benzie-Leelanau District Health Department Board of Health</b> (3 members / 2 year terms)	
4		<b>Benzie-Leelanau Environmental Health Board of Appeals</b> (3 members / 2 year terms)	
5		<b>Brownfield Redevelopment Authority (BRA)</b> (7 members / 3 year terms)	
6		<b>Construction Codes Authority Board of Appeals</b> (5 members / 5 year terms) <i>Specify the category(ies) AND list your qualifications under question #5: Select One</i>	
7		<b>Michigan Department of Health and Human Services (DHHS)</b> (2 members / 3 year terms) <i>See Agency-specific application</i>	
8	X	<b>Land Bank Fast Track Authority (LBA)</b> (7 members / 3 year terms)	
9		<b>Northern Lakes Community Mental Health Authority (CMH)</b> (2 members / 3 year terms)	
10		<b>Northern MI Regional Entity (NMRE) Substance Use Disorder Services Policy Oversight Board</b> (1 member / 3 year term)	
11		<b>Northwest Michigan Community Action Agency (NMCAA)</b> (1 member / 3 year term - <b>COMMISSIONER APPOINTMENT</b> )	COMMISSIONER APPT.
12		<b>Northwest Regional Airport Authority (NRAA)</b> (2 members / 3 year terms)	
13		<b>Parks &amp; Recreation Commission (P &amp; R)</b> (10 members / 3 year terms)	
14		<b>Planning Commission (PC)</b> (11 members / 3 year terms) <i>Specify category(ies) you qualify for AND list your qualifications for each category under question #5: Select One</i>	
15		<b>Soil Erosion, Sedimentation and Stormwater Runoff Control Ordinance Board of Appeals (SESSRC)</b> (5 members / 3 year terms)	
16		<b>Solid Waste Council (SWC)</b> (14 members / 2 year terms) <i>Specify category(ies) you qualify for AND list your qualifications under question #5: Select One</i>	
17		<b>Veterans Affairs Administrative Committee (VA)</b> (1 member / 2 year term - <i>must be a Veteran</i> )	
18		<b>Workforce Development Board (WDB)</b> (2 members / 2 year terms) <i>Must apply with Agency specific application only</i>	

7. List references and contact information (minimum of two):

Reference #1

Ty Wessell; twessell@leelanau.gov  
231-432-0066

Reference #2

Carolyn Rentenbach: peachybach@me.com  
231-883-2663

8. Are you available to attend an Open Meetings Act Training Session and a Freedom of Information Act Training Session during your first year of appointment?

Yes     No

9. Are you willing to consent to a Background Investigation?

Yes     No

10. Signature: Barbara A. Conley MD Digitally signed by Barbara A. Conley MD  
Date: 2022.07.12 18:06:02 -04'00'

## CURRICULUM VITAE

**Updated July 12, 2022**

**Barbara A. Conley, M.D.**

1/2018-2022: Hayes Locums – locum oncology physician Karmanos Cancer Institute in Petoskey, MI

5/2018 to 10/2019

Contracted Consultant: Astrix  
National Cancer Institute  
Division of Cancer Treatment and Diagnosis

7/2017 to 5/2018

Special Volunteer  
Division of Cancer Treatment and Diagnosis,  
National Cancer Institute  
National Institutes of Health  
Bethesda MD 20892

Prior positions

8/2010 to 7/2017

Associate Director  
Cancer Diagnosis Program  
Division of Cancer Treatment and Diagnosis  
National Cancer Institute, NIH, DHHS  
Rockville, MD 20850

2/2005-8/2010

Chief, Division of Hematology and Oncology  
Department of Medicine  
Michigan State University College of Human Medicine  
East Lansing, MI 48823

8/1997-12/2004

Medical Officer  
National Cancer Institute  
National Institutes of Health  
Bethesda, MD 20892

7/1987-7/1997

Instructor, Assistant and Associate Professor of Medicine  
Marlene and Stewart Greenebaum Cancer Center  
University of Maryland  
Baltimore, MD 21201

Tel: 231-632-0453

email: [tel124now@aol.com](mailto:tel124now@aol.com) or [conleyba2@gmail.com](mailto:conleyba2@gmail.com)

Home address:  
PO box 178, 505 North Mill St  
Northport, MI 49670

Citizenship: United States of America

### EDUCATION

9/1971-5/1975 B.S. Cellular Biology with honors, University of Michigan  
9/1975-3/1979 M.D. Michigan State University College of Human Medicine  
3/1979-6/1979 vacation/study  
6/1979-6/1981 Residency (Surgical) (June 1979- June 1981)  
Graduate Hospital, Philadelphia, Pennsylvania, Chief: Paul Nemir, M.D.  
7/1981-6/1984 Residency (Medical) (July 1981-June 1984)  
Greater Baltimore Medical Center, Baltimore, Maryland, Chief: Thaddeus  
Prout, M.D.  
7/1984-6/1987 Fellowship (Hematology/Oncology) (July 1984- June 1987)  
University of Maryland Cancer Center, Baltimore, Maryland, Chief:  
Joseph Aisner, M.D.  
Fall 2001: FAES Graduate School: Medical Ethics Law.  
Spring 2011: FAES Graduate School: Tech transfer introductory course

### CERTIFICATION

9/12/1984 American Board of Internal Medicine #12987  
11/10/1987 Board-certified - Medical Oncology # 99757

### LICENSURE

Medical Licensure, Michigan # 4301042358

### MAJOR RESEARCH INTERESTS

Diagnostic markers for cancer prediction and prognosis  
New Drug Development, Clinical Phase I-II Trials, Pharmacology  
Pharmacokinetic-pharmacodynamic relationships  
Treatment of carcinoma of the aerodigestive tract  
Clinical trials, head/neck cancer, gastrointestinal cancer

### FACULTY POSITIONS

7/1985-6/1987 Clinical Associate in Medicine, University of Maryland, Baltimore,  
Maryland (July 1985-June 1987)  
7/1987-6/1988 Instructor in Medicine, University of Maryland, Baltimore, Maryland (July  
1987-Jun 1988)  
7/1988-6/1993 Assistant Professor of Medicine and Oncology, University of Maryland  
Department of Medicine, University of Maryland Cancer Center,  
Baltimore, Maryland (July 1988-June 1993)

1991-1997 Affiliate Appointment, Department of Clinical Pharmacy, University of Maryland School of Pharmacy

7/1993-7/1997 Medical School Associate Professor, Medicine and Oncology; University of Maryland School of Medicine, Greenebaum Cancer Center (July 1993-Aug 1997)

1994-1997 Affiliate Appointment, Department of Pharmacology and Experimental Therapeutics, University of Maryland at Baltimore

8/1997-7/1999 Senior investigator (head/neck, gastrointestinal and lung [1998-9] cancers), Clinical Investigations Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health

1997-1999 Clinical Associate Professor (volunteer), Medicine and Oncology, University of Maryland School of Medicine, Baltimore, MD (August 1997-Dec 1999)

1998-2003 Associate staff, Clinical Center, NCI, NIH Bethesda, MD (Aug 1988-Jul 2003)

1999-2003 Chief, Diagnostic Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health; portfolio: head/neck, lung, esophageal cancers. Supervisory to branch members for other cancer sites

July 2003-Dec 2004 Head, Aerodigestive Cancer Clinical Research Section, Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute. Responsible for multidisciplinary clinical Translational research.

Jan 2004 - Dec 2004: Co-chair, Early Drug Development Coordinating Committee, Office of the Director, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland

July 2004-Dec 2004: Head, internal Phase I consult service, MOCRU, CCR, NCI

Feb 2005 – Aug 2010: Chief, Division Hematology/Oncology, Dept. Medicine, Michigan State University College of Human Medicine, East Lansing, MI

Jul 2005 – Apr 2007 Associate Director for Translational Research, Great Lakes Cancer Institute, Michigan

Apr 2007–Dec 2009: Associate Director for Translational Research, MSU-CHM/GLCI Clinical Cancer Research Center

Aug 2008- Aug 2010: Scientific Director, MSU Clinical Translational Science Institute

Feb 2009- Aug 2010: Director, Michigan State University Hematology/Oncology Fellowship Program

Aug 2010 – July 2017: Associate Director, Cancer Diagnosis Program, DCTD, NCI, NIH

Aug 2010 – July 2017: Senior Clinical Staff, Medical Oncology Branch, NCI, NIH

#### MAJOR ACADEMIC TASKS:

1. 1996-1997: Head, Cancer Prevention, Greenebaum Cancer Center at University of Maryland
2. 1995-1997: Director, Multidisciplinary Head/Neck Cancer Clinic, Greenebaum Cancer Center at University of Maryland
3. 1996-1997: Vice Chair, Institutional Review Board, University of Maryland
4. 1999: Organized Symposium on Organ Preservation Therapies for Squamous Cancers of the Head and Neck, held September 7<sup>th</sup> and 8<sup>th</sup>, 1999; Cosponsored by the Office of Rare Diseases and the National Cancer Institute, National Institute for Deafness and Other Communication Disorders, and the National Institute for Dental and Craniofacial Research
5. Executive Director, NCI Progress Review Group for Colorectal Cancer, 1999-2000.

6. Executive Director, NCI Progress Review Group for Pancreatic Cancer, 2000
7. Member, planning committee, ASCO/NCI Scientific Symposium, "Molecular Oncology for the Clinical Oncologist" Boston, October 27-28, 2001
8. Co-chair, 2<sup>nd</sup> NCI/EORTC International Meeting on Cancer Diagnostics: From Discovery to Clinical Practice, Cambridge, MD, June 26-9, 2002.
9. Member, NCI-EORTC Working Group on Clinical Trials Methodology for Prognostic and Predictive Markers. June 2000-Jul 2003
10. Consultant to Immunology Devices Panel, Center for Devices and Radiological Health, FDA. September 2002-Dec 2004
11. Co-chair, Early Drug Development Committee, Center for Cancer Research, NCI
12. Member, Committee on Research, College of Human Medicine, Michigan State University, Aug 15, 2005 – 2007.
13. Key Faculty, MSU Hematology/Oncology Fellowship Program, Feb 2005 to Aug 2010.
14. Member, Department of Medicine Promotion and Tenure Committee, June 2006 to July 2010
15. Program Director, Hematology/Oncology Fellowship Program, Feb 2009-Aug 2010
16. Member Center for Cancer Research (NCI) professional staff, Aug 2010 to Jul 2017
17. NCI representative to the AJCC November 2012 to 2015 Ex officio member: Oncology Consortium, Center for Medical Technology and Policy, Baltimore, MD
18. Leader NCI Molecular Analysis for Cancer Therapy Choice (NCI-MATCH) trial and Exceptional Responders Initiative, 2012-Jul 2017
19. Scientific Committee, NCI/AACR/EORTC Molecular Targets and Cancer Therapeutics annual meeting 2012, 2013, 2014, 2015, 2016
20. Faculty: Molecular Markers in Cancer Tutorial 2013

#### PROFESSIONAL SOCIETY MEMBERSHIPS

American Society of Clinical Oncology  
 American Association for Cancer Research  
 Alpha Omega Alpha  
 Member American Society for Clinical Oncology Awards Committee 2004-2006  
 Member, American Society for Clinical Oncology Education Committee 2006-2009  
 Board Member, Michigan Society of Hematology Oncology (MSHO) 2005 - 2010  
 Board Member, Michigan Cancer Consortium, October 2008 to 2010  
 Member, American Society for Clinical Oncology membership committee 2010 – 2013  
 Member, American Association for Cancer Research subcommittee on diagnostics policy 2014-2017

#### HONORS AND AWARDS

1975	Honors in cellular biology, University of Michigan
1987	Coauthor of abstract, American Society of Clinical Oncology - top 3%
1988	Career Development Award in Clinical Oncology, American Cancer Society
1997	William Yudkoff M.D. Memorial Award (financial recognition to a program or person involved in active research in the understanding and control of cancer)
1998-2003	Yearly sustained superior performance awards, NCI
2005	Jack Breslin Professor of Oncology, Michigan State University
2007	Alpha Omega Alpha; MSU Alumni member, December 2007
2010-2013:	Yearly sustained superior performance awards, NCI
2014:	Merit Award, National Cancer Institute

2015: Merit Award, National Cancer Institute  
2015: Merit Award (group) National Cancer Institute  
2016: Merit Award for NCI MATCH  
2017: Merit Award NCI; Exceptional Responders Initiative

#### EDITORIAL TASKS

Editorial Board, Clinical Cancer Research, January 2003 to present  
Editorial Board, Molecular Cancer Therapeutics, 2006 to present  
Editorial Board, Cancer Chemotherapy and Pharmacology, March 2009 to present  
Reviewer for Journal of National Cancer Institute  
Reviewer for Cancer Research  
Reviewer for European Journal of Cancer  
Reviewer for Journal of Clinical Oncology  
Reviewer for Cancer

#### CAMPUS ACTIVITIES

1. Member, University of Maryland Cancer Center (UMCC) Fellowship Committee, 1989-1997
2. Member, Committee to Select Trainees for UMCC NIH Training Grant, 1990-1994
3. Interviewer: Hematology-Oncology fellowship, Internal Medicine internship and Medical School candidates, University of Maryland 1987-1997
4. Member, Basic Research Subcommittee, Radiation Safety Committee, UMAB, 1992-1993
5. Member, UMCC hiring committee, 1991-1997
6. Member, Institutional Review Board, University of Maryland 1993-1997 (Vice-Chair, 1997)
7. Member NIH inter-institute committee for hepatitis C, 1998-1999
8. CIB representative to special populations committees, NCI, 1999
9. Member, NCI Quality Initiative Committee, 2000
10. Member, NCI Extramural Advisory Board, 2000-2003
11. Member, CTEP Signal Transduction Working Group, 2001-2004
12. Member, Molecular Targets Faculty, CCR, NCI, 2003-2004
13. Member, Metastasis Working Group, CCR, NCI, 2003-2004
14. Exceptional Responders and NCI-MATCH: senior investigator 2012- 2017
15. DCTD representative to NIH Undiagnosed Diseases Working Group 2012-2016
16. NCI representative Trans NIH Working Group on Clinical Genomics Implementation: 2014 - 2017

#### COMMITTEE ACTIVITIES last 15 years

1. Survivorship Workgroup Member, Michigan Cancer Consortium, Nov 2008 – 2010
2. Board Member Michigan Cancer Consortium, Nov 2008-Aug 2010
3. Member, Carrier Advisory Committee (Medical Oncology) to Medicare, State of Michigan 2009 - Jul 2010.
4. Member, Head Neck Cancer Steering Committee Rare tumor task force; 2009-2016
5. Member, DCTD Research Committee, Mar 2012 – 2016
6. External Reviewer, National Cancer Research Institute NCRI Biomarkers and Imaging CSG Progress Review, London, England, UK, June 2012
7. Planning committee member: (Institute of Medicine) National Cancer Policy Forum Workshop: Policy Issues in the Development and Adoption of Molecularly Targeted Therapies for Cancer 2014

8. Member; AACR Regulatory Science and Policy and Diagnostics Policy Subcommittee 2014-2017
9. Board of Health member, Benzie-Leelanau District Health Department: Jan 2019-Dec 2020
10. Chair, Board of Health, Benzie-Leelanau District Health Department: Jan 2021-present
11. Northport Public School Board of Education: member Jan 2021 – Dec 2021; Vice president Jan 2022 - present

TEACHING ACTIVITIES- last 15 years

- A) National Cancer Institute, NIH, DHHS:  
Senior Clinical Staff, Medical Oncology Branch, CCR, NCI, NIH 2010 – 2017; Member, Developmental Therapeutics Clinic (1 day/week clinical service, teaching fellows, developing protocols): 2010-2017
- B) NCI Medical Oncology Branch  
CMC on HPV and head and neck cancer – faculty expertise – presenter S. Ulahannan, fellow. April 6, 2012
- C) Tumor Boards - recent  
Division of Cancer Treatment and Diagnosis: Precision medicine tumor board 2012-2017

Thesis committees

- Suhlan Wu, MS (University of Maryland) 1996-7
- Keehne-Miron, Jackie PhD (nursing Michigan State University) 2007
- Darshan Parikh, Shital MS (MedTech Michigan State University) 2008

Workshops:

- a. Faculty, Markers in Cancer Tutorial: 2011, 2013, 2015
- b. Faculty: AAADV (co sponsored by ASCO and FDA) tutorial 2015, 2016

GRANT SUPPORT

Prior Support

Source of Support: NSABP  
 Period of support: 1/1/2006 – 7-1-2010  
 Project title: NSABP member

Past support: Grants/Contracts: Federal

Source of Support:	NIH, NCI, DCPC
Identification No.:	N01-CN-25440-02
Principal Investigator:	B.A. Conley, M.D.
Total Direct Funding:	\$577,152



Period of Support: 9/30/94 - 9/30/97  
Project Title: Phase II Clinical Trials of 4-Hydroxyphenyl retinamide in Oral  
Dysplastic Leukoplakia

Source of Support: NIH, NCI, DCPC  
Identification No.: N01-CN-35560  
Principal Investigator: B.A. Conley, M.D.  
Period of Support: 9/8/93 - 9/8/98  
Project Title: Phase I Studies of New Chemopreventive Agents

Source of Support: NIH, NCI, DCPC  
Identification No.: NO1CM-25440  
Period of Support: 9/30/92 - 3/31/97  
Project Title: Phase II Clinical Trials of 4HPR in Skin Actinic Keratoses

Source of Support: NIH, NCI  
Period of Support: 9/30/92 - 9/29/97  
Project Title: Phase I and II Clinical Evaluation of BRM's for the Treatment  
of Cancer

Source of Support: NIH, NCI, DCPC  
Identification No.: NO1-CN-15391-51  
Period of Support: 3/11/92 - 3/10/97  
Project Title: Phase II Clinical Trials of New Chemopreventive Agents

Source of Support: NIH, NCI  
Identification No.: NCI-CM-17504-74  
Principal Investigator: M.J. Egorin, M.D.  
Period of Support: 9/1/91 - 8/31/96  
Project Title: Master Agreement for Mechanism of Action and Biochemical  
Pharmacology Studies of Antitumor Agents

Source of Support: NIH, NCI  
Identification No.: U01-CA-69854  
Principal Investigator: D. Van Echo  
Period of Support: 3/1/95 - 2/28/98  
Project Title: Phase I Clinical Trials of Anticancer Agents

Source of Support: NIH, NCI  
Identification No.: U01-CA-31983  
Principal Investigator: Borden, E  
Period of Support: 4/1/95 - 3/31/98  
Project Title: Participation in CALGB clinical trials.

Other

Source of Support: American Cancer Society  
Identification No.: Clinical Oncology Career Development Award

Principal Investigator: B. Conley, M.D.  
Percent Effort: 50%  
Total Direct Funding: \$90,000  
Period of Support: 7/1/88 - 6/30/91  
Project Title: Optimal Clinical Use of Investigational  
Antineoplastic Agents

Source of Support: Frank C. Bressler Research Fund  
Principal Investigator: B. Conley  
Percent Effort: 0%  
Total direct Funding: \$7,665  
Period of Support: 9/1/89 - 8/31/90  
Project Title: Effect of Differentiating Agent Hexamethylene Bisacetamide  
on the Activity of DNA Interactive Agents in a Colon Cancer  
Cell Line

Source of Support: Frank C. Bressler Research Fund  
Principal Investigator: B. Conley  
Total Direct Funding: \$7,500  
Period of Support: 9/1/87 - 8/31/88  
Project Title: The Metabolism and Mechanism of Action of the  
Differentiating Agent Hexamethylene Bisacetamide

## PUBLICATIONS

### Chapters

1. Conley, B.A., Fontana, J.A. and Egorin, M.J. Differentiating Agents. In: Moossa, Schimpff, and Robson (eds) Comprehensive Textbook of Oncology, 2nd ed. Baltimore: Williams and Wilkins, 1991.
2. Conley BA and Van Echo, DA. Antineoplastic Drug Development. In: Perry (ed) The Chemotherapy Source Book, Baltimore: Williams and Wilkins, 1991; Revised 1996.
3. Conley BA. Chemotherapy in Oral Cancer: the Dentist's Role in Diagnosis, Management, Rehabilitation and Prevention, 2000; Quintessence Publishing Co., Inc. Chicago. R.A. Ord and R.H. Blanchaert, eds.
4. Conley BA. Chemoprevention of Head/Neck Cancer in Oral Cancer: the Dentists Role in Diagnosis, Management, Rehabilitation and Prevention, 2000. Quintessence Publishing Co., Inc., Chicago. RA Ord and RH Blanchaert, eds
5. Hall SJ, Kresina TF, Trauger R, Conley BA. Gene Therapy in the Treatment of Cancer in An Introduction to Molecular Medicine and Gene Therapy, 2001., Wiley-Liss, NY. Thomas F. Kresina, Ed,
6. Senderowicz AM, Van Waes C, Dancey J, Conley B. Novel agents and modalities for the treatment of squamous carcinoma of the head and neck. In press for JF Ensley, JS Gutkind, JR Jacobs and SM Lippman, eds., Head and Neck Cancer. Elsevier Science 2003

7. Conley BA, Forastiere AA, Gius D, VanWaes C. 2005. Head and Neck Cancer: 2005 Abraham J, Allegra C, eds; Bethesda Handbook of Clinical Oncology. Lippincott, Williams and Wilkins, Baltimore.
8. Donovan, E and Conley BA. Cancers of the Head and Neck: 2006 Chemotherapy Sourcebook. Eds Boyazdis, Lebowitz, Frame, Fojo; McGraw-Hill
9. Estrada DT, VanWaes C, Moni J, Conley BA. Head and Neck Cancer: 2009 Abraham J, Gulley JL, Allegra CJ, eds; Bethesda Handbook of Clinical Oncology. Lippincott, Williams and Wilkins, Baltimore
10. VanWaes C, Haglund K and Conley BA. Head and Neck Cancer: Abraham J, Gulley JL, Allegra CJ, eds; Bethesda Handbook of Clinical Oncology. Lippincott, Williams and Wilkins, Baltimore: 2013

#### Journal Articles (Refereed)

1. Pelzer, C.F., Aronson L.D., and Conley, B., "Isoelectric Focusing and Trypsin Inhibitory Capacity of Arabian Horse Serum. XIV International Congress of Genetics, Moscow, USSR (Nanke Publishers) 1978; 1:148, Ed. D.K. Belyaer.
2. Arai, K., Conley, B.A., and Nemir, P., "Reduction of Dithizone-Reactive Granules of Blood Granulocytes in Humans and Rats Bearing Tumor. J Lab Clin Med. 1983 Aug;102(2):286-97
3. Egorin, M.J., Conley, B.A., Forrest, A., Zuhowski, E.G., Sinibaldi, V., Van Echo, D.A., "Phase I Study and Pharmacokinetics of Menogaril (NSC 269148) in Patients with Hepatic Dysfunction," Cancer Research, 1987, 47, 6104-6110.
4. Conley, B.A., Hornedo, J., Abrams, J., Eisenberger, M., Hiponia, D., Aisner, J., and Van Echo, D.A., "A Phase II Trial of 4'-Deoxydoxorubicin in Advanced Nonsmall cell Lung Cancer," Cancer Treatment Reports, 1987, 71, 861-862
5. Conley, B.A., Egorin, M.J., Zuhowski, E.G., Sinibaldi, V.J., Peterson, D.E. "Salivary Concentrations of Hexamethylene Bisacetamide (HMBA) in Patients Receiving 5-Day Continuous Infusions," Cancer Chemotherapy and Pharmacology, 1988, 22, 65-68
6. Conley, B.A., Callery, P.S., Egorin, M.J., Subramanyam, B., Geelhaar, L.A., and Pan, S., "Involvement of Monoamine Oxidase and Diamine Oxidase in the Metabolism of the Cell Differentiating Agent Hexamethylene Bisacetamide (HMBA)," Life Sciences, 1988, 43, 793-800
7. Conley, B.A., Forrest, A., Egorin, M.J., Zuhowski, E.G., Sinibaldi, V., and Van Echo, D.A., "Phase I Trial Employing Adaptive Control Dosing of Hexamethylene Bisacetamide (HMBA, NSC 95580)," Cancer Research, 1989, 49, 3436-3440
8. Subramanyam, B., Callery, P.S., Egorin, M.J., Snyder, S., and Conley, B.A. "An Active, Aldehydic Metabolite of the Cell Differentiating Agent Hexamethylene Bisacetamide," Drug Metabolism and Disposition, 1989, 17(4), 398-401
9. Conley, B.A., Egorin, M.J., Sinibaldi, V., and Van Echo, D.A., "Tolerance of Full Dose

- Menogaril (NSC 269148) in Patients with Abnormal Hepatic and Renal Function," Investigational New Drugs, 1990, 8, 365-367
10. Ratain, M.J., Schilsky, R.L., Conley, B.A., and Egorin, M.J., "Pharmacodynamics in cancer therapy," Journal of Clinical Oncology, 1990, 8, 1739-1753
  11. Conley, B.A., Sewack, G.F., Egorin, M.J., Subramanyam, B., Page, J.G., and Grieshaber, C.K., "The Effect of the Monoamine Oxidase Inhibitor Isocarboxazid on the Canine Metabolism of the Cell Differentiating Agent Hexamethylene Bisacetamide," Cancer Chemotherapy and Pharmacology, 1991, 28, 33-38
  12. Rowinsky, E.K., Conley, B.A., Jones, R.J., Spivak, J.L., Auerbach, M. and Donehower, R.C., "Hexamethylene Bisacetamide in Myelodysplastic Syndrome: Effect of Five-day Exposure to Maximal Therapeutic Concentrations," Leukemia, 1992, 6, 526-534
  13. Conley, B.A., Egorin, M.J., Sinibaldi, V., Sewack, G., Kloc, C., Roberts, L., Zuhowski, E.G., Forrest, A. and Van Echo, D.A., "Approaches to optimal dosing of hexamethylene bisacetamide (NSC 95580). Cancer Chemotherapy and Pharmacology, 1992, 31, 37-45.
  14. Conley, B.A., Egorin, M.J., Whitacre, M.Y., Carter, D.C.C., Zuhowski, E.G. and Van Echo, D.A., "Phase I and Pharmacokinetic Trial of Liposome Encapsulated Doxorubicin," Cancer Chemotherapy and Pharmacology, 1993, 33, 107-112.
  15. Sheikh, M.S., Shao, Z-M., Li, X-S., Dawson, M., Jetten, A.M., Wu, S., Conley, B.A., Garcia, M., Rochefort, H., and Fontana, J.A. Retinoid-resistant estrogen receptor-negative human breast carcinoma cells transfected with retinoic acid receptor-alpha acquire sensitivity to growth inhibition by retinoids. J. Biol. Chem., 1994, 269: 21440-21447.
  16. Conley, B.A., O'Hara, S., Wu, S., Melink, T.J., Parnes, H., Pardoe, E., Egorin, M.J., and Van Echo, D.A., "Phase I Trial of Chloroquinoxaline Sulfonamide, with Correlation of Pharmacokinetics and Pharmacodynamics. Cancer Chemotherapy and Pharmacology, 1995, 37: 139-149.
  17. Aisner J, Belani CP, Kearns C, Conley BA, Hiponia D, Engstrom C., Zuhowski, E, and Egorin M. Feasibility and pharmacokinetics of Paclitaxel, carboplatin and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer. Seminars in Oncology, 1995. 22(5 Suppl 12): 17-21.
  18. Aisner J, Hiponia D, Conley B, Jacobs M, Gray W, Belani CP. Combined modalities in the treatment of head and neck cancers. Semin Oncol 1995 22 (3 Suppl 6): 28-34.
  19. Sheikh SM, Shao ZM, Li XS, Ordonez JV, Conley, BA, Wu S, Dawson MI, Han QX, Chao WR, Quick T, Niles RM, and Fontana JA. N-(4 hydroxyphenyl)-retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis, 1995, 16: 2477-2486.
  20. Parnes HL, Tait N, Conley BA and Van Echo D. A phase I study of CPT-11, weekly bolus 5-FU and leucovorin in patients with metastatic cancer. Oncology Reports 1995, 2: 1131-1134.

21. Conley, BA and Ord, RA. Current status of retinoids in chemoprevention of oral squamous cell carcinoma: an Overview. 1996: J Craniomaxillofac Surg. 24: 317-392.
22. Conley, BA, Egorin, MJ, Sridhara R, Finley R, Hemady R, Wu S, Tait N, and Van Echo DA. Phase I clinical trial of all-trans retinoic acid with correlation of pharmacokinetics and pharmacodynamics. Cancer Chemother. Pharmacol 1997; 39:291-299
23. Conley, B, Jacobs M, Ord RA, Gray W, Aisner J. A pilot trial of paclitaxel, carboplatin and concurrent radiotherapy for unresectable squamous cell carcinoma of the head and neck. Seminars in Oncology 1997; 24: s2-78- s2-80
24. Fleming GS, Waggoner SE, Wu S, Rotmensch and Conley, BA. (LETTER) Re: Response of Aleukemic Granulocytic Sarcoma to All-trans-retinoic acid plus interferon alpha-2a. J Natl Cancer Inst 1997; 89: 172,.
25. Conley B, Jacobs M, Suntharalingam M, Zacharski D, Ord RA, Gray W, and Aisner J. The role of paclitaxel/carboplatin and concurrent radiotherapy in unresectable squamous cell carcinoma of the head and neck: recent findings. Seminars in Radiation Oncology, 1997, 7 (2 Suppl 1): S1-39 - S1-41.
26. Conley,BA, Egorin MJ, Tait N, Rosen DM, Sausville EA, Dover G, Fram RA, VanEcho,DA. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clinical Cancer Research, 1998. 4: 629-634.
27. Caruso RC, Zujewski J, Iwata F, Podgor MJ, Conley BA, Ayres LM, and Kaiser-Kupfer MI. Effects of Fenretinide (4HPR) on dark adaptation. AMA Archives of Ophthalmology 1998; 116: 759-763,.
28. Conley BA, Ramsland TS, Sentz DL, Wu S, Rosen DM, Wollman M, and Eiseman JL. Antitumor activity, distribution and metabolism of 13-Cis retinoic acid as a single agent or in combination with Tamoxifen in established human MCF-7 xenografts in mice. Cancer Chemother Pharmacol. 1999; 43: 183-197.
29. Wolf GT, Forastiere A, Ang K, Brockstein B, Conley B, Goepfert H, Krause D, Lefebvre J-L, Pajak T, Pfister D, Urba S. Workshop Report: Organ Preservation Strategies in Advanced Head and Neck Cancer: Current Status and Future Directions. Head and Neck 1999; 21(8): 689-93.
30. Conley B, O'Shaughnessy J, Prindiville S, Lawrence J, Chow C, Jones E, Marino M, Kaiser-Kupfer M, Caruso RC, Podgor M, Goldspiel B, Venzon D, Danforth D, Wu S, Noone M, Goldstein J, Cowan KH, and Zujewski J. Pilot Trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide (4-HPR, Fenretinide) in combination with Tamoxifen in patients at high risk for developing invasive breast cancer. J. Clin Oncol. 2000; 18 (2): 275-83.
31. Park S-H, Gray W, Hernandez I, Jacobs M, Ord RA, Sauk J, Sawyer R, Suntharalingam M, Smith RG, Van Echo DA, Wu S and Conley BA. Phase I trial of all-trans retinoic acid in patients with treated head and neck squamous carcinoma. Clin Cancer Res 2000; 6(3): 847-854.

32. Suntharalingam M, Haas ML, Conley BA, Egorin MJ, Levy S, Sivasailam S, Herman JM, Jacobs MC, Gray WC, Ord RA, Aisner J, Van Echo DA. The use of Carboplatin and Paclitaxel with Daily Radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2000; 47(1): 49-56.
33. Compton CC, Fielding PL, Burgart LJ, Conley B, Cooper HS, Hamilton SR, Hammond MEH, Henson DE, Hutter RVP, Nagle RB, Nielsen ML, Sargent DJ, Taylor CR, Welton M, Willett C. Prognostic Factors in Colorectal Cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 979-994.
34. Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DJ, Gandara DR, O'Connell M, Shepherd FA, Johnson BE. Twenty-two years of Phase III trials for patients with advanced non-small cell lung cancer (NSCLC): Sobering results. J Clin Oncol 2001; 19(6): 1734-42.
35. Yancik, R, Ganz PA, Varricchio CG, Conley B. Perspectives on Comorbidity and Cancer in Older Cancer Patients: Approaches to Expand the Knowledge Base. J. Clin Oncol 2001; 19(4): 1147-1151.
36. Suntharalingam M, Haas ML, Van Echo DA, Haddad R, Jacobs MC, Levy S, Gray WC, Ord RA, Conley BA. Predictors of Response and Survival after Concurrent Chemotherapy and Radiation for Locally Advanced Squamous Cell Carcinomas of the Head and Neck. Cancer 2001; 91(3): 548-54.
37. Conley BA, Cumberlin R, Sandberg A, Solomon B, VanWaes, C. NIH Symposium Summary: Organ Preservation Therapies for Squamous Cancers of the Head and Neck. Clin Cancer Res, 2001; 7: 745-53
38. Tricoli JV, Schoenfeldt M, Conley BA. Detection of Prostate Cancer and Predicting Progression: Current and Future Diagnostic Markers, Clin Cancer Res, 2004; 10(12): 3943-53.
39. Sargent D., Conley BA, Allegra C, Collette L. Clinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials. J Clin Oncol, 2005; 23(9): 2020-2027.
40. Dobbin KK, Beer DG, Meyerson M, Yeatman TJ, Gerald WL, Jacobson JW, Conley B, Buetow KH, Heiskanen M, Simon RM, Minna JD, Girard L, Misek DE, Taylor JMG, Hanash S, Naoki K, Hayes DN, Ladd-Acosta C, Enkemann SA, Viale A, Giordano TJ. Inter-Laboratory Comparability Study of Cancer Gene Expression Analysis Using Oligonucleotide Microarrays. Clin Cancer Res, 2005; 11: 565-572.
41. VanWaes C, Chang A, Lebowitz PF, Druzgal CH, Chen Z, Elsayed YA, Sunwoo JB, Rudy SF, Morris JC, Mitchell JB, Camphausen K, Gius D, Adams J, Sausville EA, Conley BA. Inhibition of nuclear factor-kappaB and Target Genes During Combined Therapy with Proteasome Inhibitor Bortezomib and Re-irradiation in Patients with Recurrent Head-and-Neck Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys 2005 Dec 1;63(5):1400-12. Jul 7. epub ahead of print.
42. Acharya MR. Sparreboom A, Sauseville EA, Conley BA, Doroshow JH, Venitz J, Figg WD. Interspecies Differences in Plasma Protein Binding of MS-275, A Novel Histone Deacetylase Inhibitor. Cancer Chemotherapy and Pharmacology 2006 Feb;57(3):275-81.

Jul 19: epub ahead of print

43. Conley BA, Kummar S, Wright J. Targeting epigenetic abnormalities with histone deacetylase inhibitors. Cancer. 2006 Aug 15; 107(4):83 2-40.
44. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N. Oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol, 2007 Jul 1 25(16) 2198-204.
45. Kummar S, Gutierrez M, Gardner ER, Donovan E, Hwang K, Chung EJ, Lee MJ, Maynard K, Kalnitskiy M, Chen A, Melillo G, Ryan QC, Conley B, Figg WD, Trepel JB, Zwiebel J, Doroshow JH. Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5411-7.
46. Chandana S and Conley BA. Salivary Gland Cancers: Current Treatments, Molecular Characteristics and Promising New Therapies. Expert Review of Anticancer Therapy, 2008 8(4):645-52.
47. Al-Janadi A, Chandana S and Conley B. Histone Deacetylase: An attractive target for cancer therapy? Drugs in R&D; 2008; 9(6): 369-383
48. Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma: Shedden K, Taylor JMG, Enkemann SA, Tsao M-S, Yeatman TJ, Gerald WJ, Eschrich S, Jurisica I, Giordano TJ, Misek DE, Chang AC, Zhu CQ, Strumpf D, Hanash S, Shepherd FA, Ding K, Seymour L, Naoki K, Pennell N, Weir B, Verhaak R, Ladd-Acosta C, Golub T, Gruidl M, Sharma A, Szoke J, Zakowski M, Rusch V, Kris M, Viale A, Motoi N, Travis W, Conley B, Seshan VE, Meyerson M, Kuick R, Dobbin KA, Lively T, Jacobson JW, Beer D. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nature Med 2008; 14(8): 822-27.
49. Lefebvre J-L, Ang KK and Larynx Preservation Consensus Panel (Dr. Conley is member of Consensus Panel). Larynx Preservation Clinical Trial Design: Key issues and recommendations – a Consensus Panel summary. Head Neck. 2009 Apr;31(4):429-41.
50. Chandana S, Conley BA. Neoadjuvant Chemotherapy for Locally Advanced Squamous Cancers of the Head and Neck: Current status and future prospects. Current Opinion in Oncology 2009; 21:218–223.
51. Patel KJ, Nagpal S, Berger KL, Conley BA. A Clustering of Breast, Lung, and Fallopian Tube Cancers. Community Oncology 2009; 6: 176-78
52. Kummar S, Gutierrez ME, Gardner ER, Chen X, Figg, WD, Zajac-Kaye M, Steinberg SM, Muir CM, Yancey MA, Horneffer YR, Juwara L, Melillo G, Ivy SP, Merino M, Neckers L, Steeg PS, Conley BA, Giaccone G, Doroshow JH, Murgu AJ. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat-shock protein inhibitor, administered twice weekly in patients with advanced malignancies.

- European J Cancer 2010 Jan;46(2):340-7. Epub 2009 Nov 27.
53. Kummar S, Gutierrez ME, Gardner ER, Figg W, Melillo G, Dancey J, Sausville EA, Conley BA, Murgo AJ, Doroshow JH, Uhlenbrauck, G. A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. Cancer Chemotherapy and Pharmacology; 2010 Jan;65(2):383-9. Epub 2009 Nov 6
  54. Chandana SR, Leece CM, Gallo KA, Burra M, Conley BA. Inhibition of MLK3 decreases proliferation and increases antiproliferative activity of epidermal growth factor (EGFR) inhibitor in pancreatic cancer cell lines. Cancer Growth and Metastasis; 2010, 3: 1-9.
  55. Bhutani M, Colucci PM, Laird-Fick H, Conley BA. Management of paclitaxel-induced neurotoxicity. Oncol Rev (2010) 4:107-115 DOI 10.007/s12156-010-0048-x
  56. Patel KJ, Chandana SR, Wiese DA, Olsen B, Conley BA. Unusual presentation of large cell poorly differentiated neuroendocrine carcinoma of epiglottis. J Clin Oncol. 2010 Sep 20;28(27):e461-3. Epub 2010 Aug 2.
  57. Efeobokhan N, Makol A, Cuison RV, Minter RM, Kotaru V-P, Conley BA, Chandana SR. An unusual case of autoimmune pancreatitis presenting as pancreatic mass and obstructive jaundice: a case report and review of the literature. Journal of Medical Case Reports 2011; 5:253: doi:10.1186/1752-1947-5-253
  58. Schilsky RL, Doroshow JH, LeBlanc M, Conley BA. Development and use of integral assays in clinical trials. Clin Cancer Res 2012; 18(6): 1540-6.
  59. Williams PM, Lively TG, Jessup JM, Conley BA. Bridging the gap: Moving predictive and prognostic assays from research to clinical use. Clin Cancer Res 2012; 18(6): 1531-9.
  60. Edelman MJ, Harb WA, Pal SE, Boccia RV, Kraut MJ, Bonomi P, Conley BA, Rogers JS, Messmann RA, Garon EB. Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung. 2012; J Thorac Oncol. Oct;7(10):1618-21.
  61. Chandana SR, Kotecha R, Al-Janadi A, Chang HT, Conley BA. A Rare Case of Hairy Cell Leukemia with Brain Parenchymal Involvement – A Diagnostic Dilemma. J Clin Oncol. 2013 Apr 10;31(11):e186-8. doi: 10.1200/JCO.2012.44.8787. Epub 2013 Feb 25..
  62. McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, Mesirov JP, Polley M-Y C, Kim KY, Tricoli JV, Taylor JMG, Shuman DL, Simon RM, Doroshow JH, Conley BA. Criteria for the use of omics based predictors in clinical trials: Explanation and elaboration. BMC Medicine 2013; 11:220
  63. McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, Mesirov JP, Polley M-Y C, Kim KY, Tricoli JV, Taylor JMG, Shuman DL, Simon RM, Doroshow JH, Conley BA. Criteria for the use of omics based predictors in clinical trials. Nature 2013; 502: 317-20
  64. Polley M-Y C, Freidlin B, Korn EL, Conley BA, Abrams JS, McShane LM. Statistical and Statistical and Practical Considerations for Clinical Evaluation of Predictive



- Biomarkers. *J Natl Cancer Inst* (2013) doi: 10.1093/jnci/djt282 First published online: October 17, 2013
65. Kim K, McShane L, Conley B. Designing Biomarker Studies for Head and Neck Cancer. *HeadNeck* 2014; 36: 1069-75 Epub 21Nov 2013; doi: 10.1002/hed.23444
  66. Conley BA and Doroshow JH. Molecular Analysis for Therapy Choice. *Semin Oncol*. 2014 Jun;41(3):297-9. doi: 10.1053/j.seminoncol.2014.05.002. Epub 2014
  67. Abrams J, Conley B, Mooney M, Zwiebel J, Chen A, Welch JJ, Takebe N, Malik S, McShane L, Korn E, Williams M, Staudt L, Doroshow J. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. *Am Soc Clin Oncol Educ Book*. 2014:71-6. doi: 10.14694/EdBook\_AM.2014.34.71.
  68. Kummar S, Fleming GF, Oza AM, , Sullivan DM, Gandara DR, Naughton M, Villalona-Calero MA , Morgan R, Szabo PM, , Duan W, , Youn A, Chen A, Ji J, Allen D, Lih CJ, Mehaffey MG, Walsh WD, McGregor III PM 3rd, Steinberg SM, Williams PM, Kinders R, Conley BA, Simon RM, Doroshow JH. Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA mutant ovarian cancer. *Clin Cancer Res*. 2015 Apr 1;21(7):1574-82. doi: 10.1158/1078-0432.CCR-14-2565. Epub 2015 Jan 14. PMID: 25589624
  69. Zhao Y, Polley EC, Li MC, Lih CJ, Palmisano A, Sims DJ, Rubinstein LV, Conley BA, Chen AP, Williams PM, Kummar S, Doroshow JH, Simon RM. GeneMed: an Informatics Hub for the coordination of Next-Generation Sequencing Studies that Support Precision Oncology Clinical Trials *Cancer Inform*. 2015 Mar 19;14 (Suppl 2):45-55. doi: 10.4137/CIN.S17282
  70. Allen CT Conley B, Sunwoo JB, Van Waes C. CCR 20th Anniversary Commentary: Preclinical study of proteasome inhibitor bortezomib in head and neck cancer. *Clin Cancer Res*. 2015 Mar 1;21(5):942-3. doi: 10.1158/1078-0432.CCR-14-2550. PMID: 25733706
  71. Takebe N, McShane L, Conley B. Biomarkers: exceptional responders-discovering predictive biomarkers *Nat Rev Clin Oncol*. 2015 Mar;12(3):132-4. doi: 10.1038/nrclinonc.2015.19. Epub 2015 Feb 17
  72. Lively TG, Sachs MC, Conley BA. Translating Promising Biomarkers into Oncology Clinical Practice. January 2015 [Oncology & Hematology Review \(US\)](#) 11(01):14; DOI:[10.17925/OHR.2015.11.01.14](#)
  73. Kummar S, Williams PM, Lih CJ, Polley EC, Chen AP, Rubinstein LV, Zhao Y, Simon RM, Conley BA, Doroshow JH. Application of molecular profiling in clinical trials for advanced metastatic cancers. *J Natl Cancer Inst*. 2015 Feb 6;107(4). pii: djv003. doi: 10.1093/jnci/djv003.
  74. Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero MA, Morgan RJ Jr, Szabo PM, Youn A, Chen AP, Ji J, Allen DE, Lih CJ, Mehaffey MG, Walsh WD, McGregor PM 3rd, Steinberg SM, Williams PM, Kinders RJ, Conley BA, Simon RM, Doroshow JH. Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers,

- or BRCA-Mutant Ovarian Cancer. *Clin Cancer Res*. 2015 Apr 1;21(7):1574-82. doi: 10.1158/1078-0432.CCR-14-2565. Epub 2015 Jan 14.
75. Siu LL, Conley BA, LoRusso PM. Next Generation Sequencing to Guide Clinical Trials. *Clin Cancer Res* 201521(20): 4536-44.
  76. Sims DJ, Harrington RD, Polley EC, Forbes TD, Mehaffey MG, McGregor PM 3rd, Camalier CE, Harper KN, Bouk CH, Das B, Conley BA, Doroshow JH, Williams PM, Lih CJ. Plasmid-Based Materials as Multiplex Quality Controls and Calibrators for Clinical Next-Generation Sequencing Assays. *J Mol Diagn*. 2016 May;18(3):336-49.
  77. Williams PM, Conley BA. Clinical Application of Liquid Biopsies. *JAMA Oncol*. 2016 Aug 1;2(8):1003-5.
  78. Conley BA, Sorg BS, Tricoli JV. Implications and Opportunities of precision medicine in rare malignancies. *Expert Opinion on Orphan Drugs* 2016, 4:9, 953-960, DOI: 10.1080/21678707.2016.1214071
  79. Conley BA and Flaherty KT. Molecular analysis for therapy choice (NCI-MATCH): A Precision Medicine Signal-Seeking Trial in Oncology. *Personalized Med in Oncol*; 2016; 5(8): 322-330
  80. Lih CJ, Sims DJ, Harrington RD, Polley EC, Zhao Y, Mehaffey MG, Forbes TD, Das B, Walsh WD, Datta V, Harper KN, Bouk CH, Rubinstein LV, Simon RM, Conley BA, Chen AP, Kummar S, Doroshow JH, Williams PM. Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial. *J Mol Diagn*. 2016 Jan;18(1):51-67. doi: 10.1016/j.jmoldx.2015.07.006. Epub 2015 Nov 18. PMID: 26602013
  81. Lih CJ, Harrington RD, Sims DJ, Harper KN, Bouk CH, Datta V, Yau J, Singh RR, Routbort MJ, Luthra R, Patel KP, Mantha GS, Krishnamurthy S, Ronski K, Walther Z, Finberg KE, Canosa S, Robinson H, Raymond A, Le LP, McShane LM, Polley EC, Conley BA, Doroshow JH, Iafrate AJ, Sklar JL, Hamilton SR, Williams PM. Analytical Validation of the Next Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial (NCI-MATCH, EAY131); *J Mol Diagn*. 2017 Mar;19(2):313-327
  82. Cristofaro JV, Ansher SS, Zwiebel J, Ivy P, Conley B, Abrams JS, Doroshow JH. The NCI Formulary: a public-private partnership providing investigators access to investigational anti cancer agents. *Clin Pharmacol Ther*. 2016 Dec 16.
  83. Kim KY, Le QT, Yom SS, Pinsky BA, Bratman SV, Ng RH, El Mubarak HS, Chan KC, Sander M, Conley BA. Current State of PCR-Based Epstein-Barr Virus DNA Testing for Nasopharyngeal Cancer. *J Natl Cancer Inst*. 2017 Apr 1;109(4): doi: 10.1093/jnci/djx007.
  84. Kim KY, Le QT, Yom SS, Ng RHW, Chan KCA, Bratman SV, Welch JJ, Divi RL, Petryshyn R, Conley BA. Clinical utility of Epstein Barr Virus DNA testing in the treatment of nasopharyngeal carcinoma patients. Accepted to *Int J Radiat Oncol Biol Phys* 2017; 98(5): 996-1001.

85. O'Sullivan Coyne G, Ivy SP, Conley BA. Use of precision methods to accelerate drug development in oncology. *Expert Rev of Precision Med and Drug Dev.* 2017, Published online: 03 Apr 2017 <http://dx.doi.org/10.1080/23808993.2017.1311773>
86. Tricoli JV, Boardman LA, Patidar R, Sindiri S, Jang JS, Walsh WD, McGregor PM III, Camalier CE, Mehaffey MG, Furman WL, Bharami A, LM, Williams PM, Lih C-J, Conley BA and Khan J. A Mutational Comparison of Adult and Adolescent and Young Adult (AYA) Colon Cancer. *Cancer.* 2018 March 01; 124(5): 1070–1082. *Cancer.* 2018 Mar 1;124(5):1070-1082. doi: 10.1002/cncr.31136. Epub 2017 Nov 30.PMID: 29194591
87. Morfouace M, Hewitt SM, Salgado R, Hartmann K, Litiere S, Tejpar S, Golfinopoulos V, Lively T, Thurin M, Conley B, Lacombe D. A transatlantic perspective on the integration of Immuno-Oncology Prognostic and Predictive Biomarkers in innovative clinical trial design. *Semin Cancer Biol* 2018; 52(Pt2)158-165.
88. Ossandon MR, Agrawal L, Bernhard EJ, Conley BA, Dey SM, Divi RL, Guan P, Lively TG, McKee TC, Sorg BS, Tricoli JV. Commentary: Circulating tumor DNA assays in Clinical Cancer Research. *J Nat Cancer Inst* 2018; 110(9): 929-934.
89. Speranza g, Anderson L, Chen AP, Do K, Eugeni M, Weil M, Rubinstein L, Majerova E, Collins J, Horneffer Y, Juwara L, Zlott J, Bishop R, Conley BA, Streicher H, Tomaszewski J, Doroshov JH, Kummar S. First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile. *Invest New Drugs* 2018; 36(2): 230-239.
90. Tsimberidou AM, Said R, Staudt LM, Conley BA, Takebe N. Defining, Identifying, and Understanding "Exceptional Responders" in Oncology Using the Tools of Precision Medicine. *Cancer J.* 2019 Jul/Aug;25(4):296-299. doi: 10.1097/PPO.0000000000000392. PMID: 31335394
91. Azad NS, Gray RJ, Overman MJ, Schoenfeld JD, Mitchell EP, Zwiebel JA, Sharon E, and Streicher H, Li S, McShane LM, Rubinstein L, Patton DR, Williams PM, Coffey B, Hamilton SR, Bahary N, Suga JM, Hatoum H, Abrams JS, Conley BA, Arteaga CL, Harris L, O'Dwyer PJ, Chen AP, Flaherty KT. Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study. *J Clin Oncol* 2019; online Nov 25, 2019; DOI <https://doi.org/10.1200/JCO.19.00818>; *J Clin Oncol.* 2020 Jan 20;38(3):214-222. doi: 10.1200/JCO.19.00818. Epub 2019 Nov 25.PMID: 31765263
92. Jhaveri K, Wang V, Makker V, Luoh S-W, Mitchell E, Zwiebel J, Sharon E, Gray R, Li S, McShane L, Rubinstein L, Patton D, Williams P, Hamilton S, Conley B, Arteaga C, Harris L, O'Dwyer P, Chen A, Flaherty K. Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Sub-protocol Q. Aug 27, 2019 online *Annals of Oncology*, mdz291, <https://doi.org/10.1093/annonc/mdz291> . *Ann Oncol.* 2019 Nov 1;30(11):1821-1830. doi: 10.1093/annonc/mdz291.PMID: 31504139
93. Johnson D, Zhao F, Noel M, Riely G, Mitchell E, Wright J, Chen H, Gray R, Li S, McShane L, Rubinstein L, Patton D, Williams M, Hamilton S, Conley B, Arteaga C, Harris L, O'Dwyer P, Chen A, and Flaherty K. Trametinib in cancers harboring BRAF

- non-V600 mutations or fusions: results from NCI-MATCH (EAY131). *Clin Cancer Res*. 2020 Apr 15;26(8):1812-1819. doi: 10.1158/1078-0432.CCR-19-3443. Epub 2020 Jan 10. PMID: 31924734
94. Conley BA, Staudt L, Takebe N, Wheeler DA, Wang L, Cardenas MF, Korchina V, Zenklusen JC, McShane LM, Tricoli JT, Williams PM, Lubensky I, O'Sullivan-Coyne G, Kohn E, Little R, White J, Malik S, Harris LN, Mann B, Weil C, Tarnuzzer R, Karlovich C, Rodgers B, Shankar L, Jacobs PM, Nolan T, Berryman SM, Gastier-Foster J, Bo. wen J, Leraas K, Shen H, Laird PW, Esteller M, Miller V, Johnson A, Edmondson EF, Ivy SP. The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. *J Natl Cancer Inst*. 2021 Jan 4;113(1):27-37. doi: 10.1093/jnci/djaa061.
95. Flaherty KT, Gray R, Chen A, Li S, Patton D, Hamilton SR, Williams PM, Mitchell EP, Iafrate J, Sklar J, Harris LN, McShane LM, Rubinstein LV, Sims DJ, Routbort M, Coffey B, Fu T, Zwiebel JA, Little RF, Marinucci D, Catalano R, Magnan R, Kibbe W, Weil C, Tricoli JV, Alexander B, Kumar S, Schwartz GK, Meric-Bernstam F, Lih C-J, McCaskill-Stevens W, Caimi P, Takebe N, Datta V, Arteaga CL, Abrams JS, Comis R, O'Dwyer PJ, Conley BA. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. *JNCI: Journal of the National Cancer Institute*, djz245, <https://doi.org/10.1093/jnci/djz245>; Published: 10 January 2020
96. Flaherty KT, Gray RJ, Chen AP, Li S, McShane LM, Patton D, Hamilton SR, Williams PM, Iafrate AJ, Sklar J, Mitchell EP, Harris LN, Takebe N, Sims DJ, Coffey B, Fu T, Routbort M, Zwiebel JA, Rubinstein LV, Little RF, Arteaga CL, Comis R, Abrams JS, O'Dwyer PJ, Conley BA. For the NCI-MATCH team. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: NCI-MATCH (Molecular Analysis for Therapy Choice). *J Clin Oncol*. 2020 Nov 20;38(33):3883-3894. doi: 10.1200/JCO.19.03010. Epub 2020 Oct 13. PMID: 33048619
97. Johnson DB1, Zhao F, Noel M, Riely GJ, Mitchell EP, Wright JJ, Chen HX, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Trametinib activity in patients with solid tumors and lymphomas harboring BRAF non-V600 mutations or fusions: results from NCI-MATCH (EAY131). *Clin Cancer Res* 2020 April 15; 26(8): 1812–1819. doi:10.1158/1078-0432.CCR-19-3443.
98. Chae YK\*, Hong F, Vaklavas C\*, Cheng HH, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Mansfield A, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. A Phase II Study of AZD4547 in Patients with Tumors harboring Aberrations in the FGFR Pathway: Results from the NCI-MATCH Trial (EAY131) Sub-protocol W. *J Clin Oncol*. 2020 Jul 20;38(21):2407-2417. doi: 10.1200/JCO.19.02630. Epub 2020 May 28. PMID: 32463741
99. Salama AKS, Li S, Macrae ER, Park J-I, Mitchell EP, Zwiebel JA, Chen HX, Gray RJ, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR<sup>1</sup>, Armstrong DK, . Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT et al. Dabrafenib and Trametinib in patients with tumors with BRAF V600E mutation: Results of the NCI-MATCH trial subprotocol H. *J Clin Oncol*. 2020 Nov 20;38(33):3895-3904. doi: 10.1200/JCO.20.00762. Epub 2020 Aug 6. PMID: 32758030

100. Chen A, Flaherty K, O'Dwyer PJ, Giantonio B, Marinucci D, Lee J-W, Railey E, Smith ML, White C, Conley BA. Tumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial. *JCO Precis Oncol*. 2020 Oct 5;4:PO.20.00217. doi: 10.1200/PO.20.00217. eCollection.
101. Kalinsky K, Hong F, McCourt CK, Sachdev JC, Mitchell EP, Zwiebel JA, Doyle LA, McShane LM, Li S, Gray RJ, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, O'Dwyer PJ, Harris LN, Arteaga CL, Chen AP, Flaherty KT. Assessment of AKT Inhibitor Capivasertib 2 (AZD5363) Therapy in Patients With a Tumor With 3 an AKT E17K-Mutated Tumor 4: A Nonrandomized Controlled Trial. Accepted *JAMA Oncol* 2020
102. Wheeler DA, Takebe N, Hinoue T, Hoadley KA, Cardenas MF, Hamilton AM, Laird PW, Wang L, Johnson A, Dewal N, Miller V, Piñeyro D, Castro de Moura M, Esteller M, Shen H, Zenklusen JC, Tarnuzzer R, McShane LM, Tricoli JV, Williams PM, Lubensky I, O'Sullivan-Coyne G, Kohn EC, Little RF, White J, Malik S, Harris L, Weil C, Chen AP, Karlovich C, Rodgers B, Shankar L, Jacobs P, Nolan T, Hu J, Muzny DM, Doddapaneni H, Korchina V, Gastier-Foster J, Bowen J, Leraas K, Edmondson EF, Doroshow JH, Conley BA, Ivy SP, Staudt LM. *Cancer Cell*. 2020 Nov 16:S1535-6108(20)30546-8. doi: 10.1016/j.ccell.2020.10.015. Online ahead of print. PMID: 33217343
103. Cleary JM, Wang V, Heist RS, Kopetz ES, Mitchell EP, Zweibel JA, Kapner JS, Chen HX, Li S, Gray RJ, McShane LM, Rubinstein LV, Patton DR, Meric-Bernstam F, Dillmon MS, Williams PM, Hamilton SR, Conley BA, Aguirre AJ, O'Dwyer PJ, Harris LN, Arteaga CL, Chen AP, Flaherty KT. Differential outcomes in codon 12/13 and codon 61 *NRAS*-mutated cancers in the phase 2 NCI-MATCH trial of binimetinib in patients with *NRAS*-mutated tumors. Accepted to *Clinical Cancer Research* Jan 2021.
104. Senthil Damodaran, Fengmin Zhao, Dustin A. Deming, Edith P. Mitchell, John Joseph Wright, Laurence A Doyle, Robert James Gray, Shuli Li, Lisa M McShane, Larry V Rubinstein, David R Patton, Mickey Williams, Stanley R. Hamilton, Jennifer Marie Suga, Barbara A. Conley, Carlos L. Arteaga, Lyndsay Harris, Peter J. O'Dwyer, Alice P. Chen, Keith Flaherty. Phase 2 Study of Copanlisib in Patients with Tumors with *PIK3CA* Mutations (*PTEN* Loss Allowed): NCI MATCH EAY131-Z1F. Submitted to *J Clin Oncol* March 2021
105. K.B. Wisinski, Y. Flamand, \*M. Wilson, J.J. Luke, H.A. Tawbi, F. Hong, E.P. Mitchell, J.A. Zweibel, H. Chen, R.J. Gray, S. Li, L.M. McShane, L.V. Rubinstein, D. Patton, P.M. Williams, S.R. Hamilton, R.J. Behrens, K.P. Pennington, B.A. Conley, C.L. Arteaga, L.N. Harris, P.J. O'Dwyer, A.P. Chen, K.T. Flaherty. Trametinib in Patients with NF1, GNAQ or GNA11 Mutant Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2. Submitted to *Ann Oncol*.
106. Krop IE, Jegede OA, Grilley-Olsen JE, Lauring JD, Mitchell EP, Zwiebel JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Kono SA, Ford JM, Garcia AA, Sui SD, Siegel RD, Solomovitz BM, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Taselisib in *PIK3CA* Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. *JCO Precision*

- 107.** Mansfield AS, Wei Z, Mehra R, Shaw AT, Lieu CH, Forde PM, Drilon AE, Mitchell EP, Wright JJ, Takebe N, Sharon E, Hovelson D, Tomlins S, Zeng J, Poorman K, Malik N, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial, *npj Precis. Onc.* **6**, 13 (2022). <https://doi.org/10.1038/s41698-022-00256-w>
- 108.** Bedard PL, Li S, Wisinski KB, Yang ES, Lemaye SA, Mitchell EP, Zwiebel JA, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. "Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) sub-protocol EAY131-B," Accepted for publication in *JCO Precision Oncology*, June 2022.

Non-peer reviewed publications and invited reviews:

1. Conley, Barbara A., Cheson, Bruce D. Clinical Trials Referral Resource: Head and Neck Cancer. *Oncology* (Huntington) 1997;11: 1527-1530.
2. Conley BA, Kaplan RS, and Arbuik SG. NCI Clinical Trials Program in Colorectal Cancer. *Cancer Chemotherapy and Pharmacology* 1998; 42: S75-S79.
3. Conley BA, Smiley JK, Cheson BD. Clinical Trials Referral Resource: Multimodality Approaches for Advanced Esophageal Cancer. *Oncology* (Huntington) 1998; 12(6): 856-865.
4. Conley BA, Smiley JK, Cheson BD. Clinical trials referral resource: Clinical Trials in Gastric Cancer. *Oncology* (Huntington) 1999; 12(12): 1751-2.
5. Conley BA, Smiley JK and Cheson BD. Clinical Trials Referral Resource: NCI Clinical Trials in Colon Cancer *Oncology*, (Huntington) 1999; 13(6): 814-820.
6. Conley BA, and Cheson BD. Clinical Trials Referral Resource: NCI Clinical Trials for Advanced Squamous Cell Carcinoma of the Head and Neck. *Oncology* (Huntington): 2000
7. Conley BA, Enos RA, Cheson BD. Clinical Trials Referral Resource: Targeted Therapy in Squamous Cell Cancers of the Head and Neck. *Oncology* (Huntington) 2002; 16(5): 621-26.
8. Conley BA and Taube SE. Prognostic and Predictive Markers in Cancer. *Disease Markers* 2004; 20: 35-43.
9. Conley BA. Treatment of Advanced Head and Neck Cancer: What lessons have we learned? Editorial for *J. Clin Oncol* 2006; 24(7): 1023-5.
10. Conley BA. Salivary Gland Tumors in ASCO Education Book, 2007

11. Conley BA. Genomically guided cancer treatments: from “promising” to “clinically useful”. J Natl Cancer Inst. 2015 May 28;107(7). pii: djv168. doi: 10.1093/jnci/djv168

Abstracts (65 abstracts 1986-2007): selected abstracts since 2008 are listed below:

1. Chandana SR, Leece C, Gallo KA, Madhukar B, Conley BA. Inhibition of MLK3 decreases proliferation and increases antiproliferative activity of epidermal growth factor receptor (EGFR) inhibitor in pancreatic cancer cell lines. Presented at the 2008 American Association for Cancer Research meeting, San Diego, CA
2. Chandana SR, Leece C, Conley BA. Simultaneous targeting of the epidermal growth factor receptor (EGFR) and HSP90 in pancreatic cancer. Presented at 2009 American Association for Cancer Research Meeting, Denver, CO
3. Conley BA, Leece CL, Chandana S, Dowlashati S. Role of Mixed Lineage Kinase 3 in Response of Head and Neck Squamous Cancer Cell Lines to EGFR Inhibition. Presented at 2009 American Society of Clinical Oncology Meeting, Orlando, FL
4. Harb W, Sauseville E, Boccia R, Pal SE, Kraut M, Conley BA, Garon E, Simon G, Govinda R, Bonomi P, Messmann R. EC-FV-03: A phase II Study of EC145 (folate-receptor targeted therapy) in Patients with Advanced Lung Cancer, presented as an Electronic Poster (e-poster) and highlighted in a Poster Discussion Session at the 13th World Conference on Lung Cancer, San Francisco, USA from 31 July to 4 August 2009.
5. Chandana SR, Leece CM, Conley BA. HSP90 inhibition down regulates EGFR and its effector signaling proteins in pancreatic cancer cell lines Amer Assoc for Cancer Res meeting 2010
6. Harb WA, Conley BA, LoRusso P, Sausville EA, Chandana SR, Hamm M, Casetta L, Carter J, Perez WJ, Messmann RA. A Phase I study of the folate targeted conjugate EC4089 in patients with refractory or metastatic cancer. Amer Soc Clin Oncol 2010.
7. J. C. Morris, D. E. Citrin, L. Nottingham, S. F. Rudy, N. Harold, T. Cooley-Zgela, D. Goldstein, J. J. Wright, B. A. Conley, C. Van Waes; Phase I study of proteasome inhibitor bortezomib (B) concurrent with re-irradiation therapy (re-RT) for recurrent squamous cell carcinoma of the head and neck (SCCHN). Amer Soc Clin Oncol 2010.
8. Rischin D, Spigel D, Adkins D, Wein R, Arnold S, Davis ML, Singhal N, Conley B, Dong J, Sidhu R. Panitumumab (pmab) regimen in second-line monotherapy (PRISM) in patients (pts) with metastatic or recurrent (M/R) squamous cell carcinoma of the head and neck (SCCHN): interim safety analysis. ESMO 2010.
9. Conley BA, Lively T, Jessup J, Williams PM. Clinical Assay Development Program. Presented at Molecular Markers in Cancer, Brussels, BE October 27-29, 2011.
10. Kummar S, Oza AM, Fleming GF, Sullivan D, Gandara DR, Erlichman C, Villalona-Calero MA, Morgan R, Chen AP, Ji JJ, Allen D, Lih C-J, Steinberg SM, Williams PM, Conley BA, Doroshow JH. Randomized trial of oral cyclophosphamide © with or

- without veliparib (V), an oral poly(AD-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. *J Clin Oncol* 30, 2012 (suppl; abstr 5020)
11. Lih, J, Sims D, Mehaffey M, Forbes T, McGregor P, Walsh B, Munroe D, Conley B, Kummar S, Polley E, Zhao Y, Simon R, Williams M. Moving Next Generation Sequencing into the Clinical Realm: Detection of Somatic Mutations in Cancer by Targeted Amplicon Sequencing. presented at the Molecular Markers in Cancer Meeting (ASCO, NCI, EORTC) October 2012
  12. Conley BA, Lively T, Jessup J, Williams PM. Clinical Assay Development Program. Presented at Molecular Markers in Cancer, Hollywood, FL October 2012
  13. Kummar S, Williams M, Lih J, Chen A, Rubinstein L, Antony R, Polley E, Zhao Y, Conley B, Simon R, Doroshow JH. NCI MPACT: National Cancer Institute Molecular Profiling based Assignment of Cancer Therapy: ASCO 2014
  14. Conley BA. Precision Medicine Initiatives: MATCH and Exceptional Responders: presented to the National Cancer Advisory Board, Dec 2013
  15. Conley BA, NCI Precision Medicine Initiatives. ICRP Annual meeting, Redondo Beach, CA April 2014
  16. Conley BA. NCI Precision Medicine Initiatives: ASCO Jun, 2014
  17. Conley BA. Considerations in the Implementation of clinical trials with an integral next-generation sequencing assay: Challenges and Opportunities: 2014 Next Generation Sequencing Summit, Washington DC, August 2014
  18. Conley BA. NCI-MATCH and precision medicine trials: presented at Carle Cancer Clinic annual education meeting, Champaign-Urbana, IL, September 29, 2017
  19. Conley BA, Hamilton SR, Li S, Gray RJ, Patton DR, O'Dwyer PJ, Comis RL, Abrams JS, Azad NS, Overman MJ, Schoenfeld JD, Williams PM, Tricoli JV, Sharon E, Streicher HZ, Harris LN, Chen AP, Flaherty KT. Prevalence of mismatch repair deficiency (dMMR) in the NCI Molecular Analysis for Therapy choice (NCI-MATCH or EAY131) Population. Presented at the AACR/NCI/EORTC Molecular Targets and Cancer Therapeutics conference, Philadelphia, PA, Oct 26-30, 2017 (poster)
  20. Harris L, Chen A, O'Dwyer P, Flaherty K, Hamilton S, McShane L, Gray R, Li S, Mitchell E, Dragaud D, Williams M, Sklar J, Iafrate AJ, Patton D, Little RF, Zwiebel J, Abrams J, Doroshow J, Conley B. Update on the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH/EAY131) precision medicine trial. Presented at the AACR/NCI/EORTC Molecular Targets and Cancer Therapeutics conference, Philadelphia, PA, Oct 26-30, 2017 (poster)
  21. Azad N, Overman M, Gray R, Schoenfeld J, Arteaga C, Coffey B, Patton D, Li S, McShane L, Rubinstein L, Harris L, Comis R, Abrams J, Williams PM, Mitchell E, Zwiebel J, Sharon E, Streicher H, O'Dwyer PJ, Hamilton S, Conley B, Chen A, Flaherty K. Nivolumab in mismatch repair deficient (MMRd) non-colorectal cancers: NCI-MATCH trial (Molecular Analysis for Therapy Choice) arm Z1D preliminary results.



Presented at Society for Immunotherapy and Cancer 32<sup>nd</sup> meeting Nov 8-12, 2017.

22. Conley BA. Using molecular features of tumors to discover signals of activity for targeted treatments in cancer: lessons learned from NCI precision oncology trials. Amer Assoc Cancer Research 2018 Educational session: Basket trials for Precision Oncology
23. Jhaveri KL, Makker V, Wang XV, Chen AP, Flaherty KT, Conley BA, O'Dwyer PJ, Williams PM, Hamilton SR, Harris L, McShane L, Rubinstein L, Gray RJ, Li S, Mitchell EP, Patton D, Moscow J, Zwiebel JA, Arteaga CL, Luoh S-W. Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: results from the National Cancer Institute (NCI)-Molecular Analysis for Therapy Choice (MATCH) trial. Presented oral session ASCO annual meeting 2018
24. Krop IE, Grilley-Olson JE, Jegede O, Lauring JD, Hamilton SR, Zwiebel JA, Li S, Rubinstein LW, Doyle A, Patton DR, Mitchell EP, Arteaga CL, Conley BA, Sims D, Harris LN, Chen AP, Flaherty KT. Results from Molecular Analysis for Therapy Choice (MATCH) Arm I: Taselisib for PIK3CA –mutated tumors. Presented oral session ASCO annual meeting 2018
25. Chae YK, Vaklavas C, Cheng HH, Hong F, Harris L, Mitchell E, Zwiebel J, Rubinstein L, McShane L, Gray R, Li S, Ivy SP, Ansher S, Hamilton SR, Williams PM, Patton D, Tricoli J, Arteaga CL, Conley B, O'Dwyer P, Chen A, Flaherty K. A phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway. Molecular Analysis for Therapy Choice (MATCH) Arm W. Presented oral session ASCO annual meeting 2018
26. Kalinsky K, Hong F, McCourt CK, Sachdev JC, Mitchell EP, Zwiebel JA, Doyle LA, McShane LM, Li S, Gray RJ, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, O'Dwyer PJ, Harris LN, Arteaga CL, Chen AP, Flaherty KT. AZD5363 in patients with tumors with AKT mutations: NCI-MATCH subprotocol EAY131-Y, A trial of the ECOG-ACRIN Cancer Research Group (EAY131-Y). Presented at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics meeting Nov 2018.
27. Bedard PL, Li S, Wisinski KB, Yang ES, Limaye SA, Mitchell EP, Zwiebel JA, Moscow J, Gray RJ, McShane LM, Rubenstein LV, Patton DR, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. NCI Molecular analysis for therapy choice (NCI-MATCH EAY131) Arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations. Poster. AACR annual meeting 2019
28. Kummar S, Li S, Reiss KA, Ford JM, Mitchell EP, Zwiebel JA, Takebe N, Gray RJ, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Brufsky A, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. NCI-MATCH EAY131-Z1-I: Phase II study of AZD1775, a Wee-1 kinase inhibitor, in patients with tumors containing BRCA1 and BRCA2 mutations. Poster. AACR annual meeting 2019.
29. Clark AS, Hong F, Finn RS, DeMichele AM, Mitchell EP, Zwiebel J, Amaldez FI, McShane LM, Li S, Gray RJ, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Copur MS, Kasban SS, Thind R, Conley BA, O'Dwyer PJ, Harris LN, Arteaga CL, Chen AP, Flaherty KT. NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) Arm

- Z1B: Phase II trial of palbociclib for CCND 1,2, or 3 amplified tumors. Poster. AACR annual meeting 2019.
30. Tricoli JV, Zane L, Harrington R, Yee L, Harper K, Chang T-C, Kim B, Sims D, Harris LN, Chen AP, Flaherty KT, O'Dwyer PJ, Conley BA, Winter C, Lee J, Williams PM, Patton D, Sklar J, Tsongalis G, Hamilton SR, Iafrate J, Karlovich C, et al. Design and development of the Molecular Analysis for Therapy Choice (NCI-MATCH) designated laboratory network. ASCO annual meeting 2019 poster discussion.
  31. Salama AKS, Li S, Macrae ER, Park J-I, Mitchell EP, Zwiebel JA, Chen HX, Gray RJ, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Armstrong DK, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Dabrafenib and trametinib in patients with tumors with BRAF V600 mutations: Results of the NCI-MATCH trial arm H. Oral presentation ASCO Annual meeting 2019.
  32. Harris LN, Gray R, Conley BA, Chen AP, Flaherty KT, Hamilton SR, Williams PM, Karlovich C, Patton D, Li S, McShane LM, Rubinstein LR, Mitchell E, Tricoli JV, Little RF, Arteaga C, O'Dwyer PJ for the NCI-MATCH team. National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH): a successful precision medicine signal-seeking trial in patients with rare variants and refractory malignancies. Presented at the EORTC-NCI-AACR Conference on Molecular Targets and Cancer Therapeutics October 2019.
  33. Chen A, Li S, Coffey B, Tricoli J, Hamilton S, Williams M, Mitchell E, Patton D, Gray R, McShane L, Rubinstein L, Arteaga C, O'Dwyer P, Harris L, Conley B, Flaherty K. Adolescent and young adult (AYA) cohort of the NCI MATCH clinical trial (EAY131). Presented at the EORTC-NCI-AACR Conference on Molecular Targets and Cancer Therapeutics October 2019.
  34. RM, Wang V, Hyman DM, Grivas P, Mitchell EP, Wright JJ, Sharon E, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty. Activity of Trastuzumab and Pertuzumab in patients with non-Breast/Gastroesophageal HER2-amplified Tumors: Results of the NCI-MATCH trial (EAY131) Subprotocol J. ESMO 2020
  35. Mita AC, Wei Z, Mayer IA, Cheng H, Mitchell EP, Wright JJ, Ivy SP, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Erdafitinib in patients with tumors harboring FGFR gene mutations or fusions: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol K2. To be presented AACR-NCI-EORTC Virtual Conference, November 2021
  36. Tsao AS, Song Z, Ho AL, Mehnert JM, Mitchell EP, Wright JJ, Takebe N, Gray RJ, Wang V, McShane L, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris L, O'Dwyer PJ, Chen AP, Flaherty K. Phase II study of vismodegib in patients with *SMO* or *PTCH1* mutated tumors: Results from NCI-MATCH

ECOG-ACRIN Trial (EAY131) Subprotocol T. Amer Soc Clin Oncol Ann Mtg poster presentation June 2022.

## Leelanau County Appointment Application to Boards/Commissions/Committees/Authorities

The Leelanau County Board of Commissioners is committed to seeking qualified and interested citizens to participate in public service through appointment to various Boards/Commissions/Committees/Authorities. To be considered for an appointment, a citizen must be a resident of Leelanau County, a registered voter of Leelanau County, and must have an application on file in the Administrator's Office. Applications will expire four (4) years from the issue date.

**Please type or print legibly**

Name: David G King	Date: 10/29/2021
Address: 10275 E. Apple Ridge Drive, Traverse City, MI 49684	
Occupation: Attorney	
Daytime Telephone: (231) 929-3190 (office); (773) 682-8010 (cell)	
Email Address: david.graham.king@gmail.com	

1. Are you a resident of Leelanau County?       Yes       No
2. Are you a registered voter of Leelanau County?  Yes       No

Township or Village: Elmwood Township

3. Can you regularly attend scheduled meetings? Day:  Yes       No  
 Evening:  Yes       No

4. State your understanding of citizen involvement on Leelanau County Boards, Commissions, Committees, and Authorities (use page 4 if you need additional space).

To provide valuable and effective perspective to the Board of Commissioners as a community member on issues affecting the County at-large, as directed by Board ordinance and consistent with state and federal law.

5. What are your qualifications for appointment?

I'm a hard working and dedicated public-service attorney. I have worked for the United States Court system for seven years, and before that represented (amongst others) various local and state public entities. I am well-versed in how public boards operate and currently sit on the Board of Directors of The Children's House. And as a professional raising my children in the County, I am deeply committed to ensuring the County remains a place where we can all proudly call home.

I have also attached my resume.

6. Please indicate below with an X any/all Boards/Commissions/Committees/Authorities you are willing to serve on. Please place two Xs on the one(s) you feel strongly about:

	X	Board/Commission/Committee/Authority	Have you served on this board in the past? Give dates.
1		<b>Area Agency on Aging of Northwest Michigan (AAA)</b> (1 member / 2 year terms)	
2		<b>Bay Area Transportation Authority (BATA)</b> (2 members / 3 year terms)	
3		<b>Benzie-Leelanau District Health Department Board of Health</b> (3 members / 2 year terms)	
4		<b>Benzie-Leelanau Environmental Health Board of Appeals</b> (3 members / 2 year terms)	
5	X	<b>Brownfield Redevelopment Authority (BRA)</b> (7 members / 3 year terms)	No
6		<b>Construction Codes Authority Board of Appeals</b> (5 members / 5 year terms) <i>Specify the category(ies) AND list your qualifications under question #5: Select One</i>	
7		<b>Michigan Department of Health and Human Services (DHHS)</b> (2 members / 3 year terms) <i>See Agency-specific application</i>	
8	X	<b>Land Bank Fast Track Authority (LBA)</b> (7 members / 3 year terms)	No
9		<b>Northern Lakes Community Mental Health Authority (CMH)</b> (2 members / 3 year terms)	
10		<b>Northern MI Regional Entity (NMRE) Substance Use Disorder Services Policy Oversight Board</b> (1 member / 3 year term)	
11		<b>Northwest Michigan Community Action Agency (NMCAA)</b> (1 member / 3 year term - <i>COMMISSIONER APPOINTMENT</i> )	
12		<b>Northwestern Regional Airport Commission (NRAC)</b> (2 members / 3 year terms)	
13		<b>Parks &amp; Recreation Commission (P &amp; R)</b> (10 members / 3 year terms)	
14	XX	<b>Planning Commission (PC)</b> (11 members / 3 year terms) <i>Specify category(ies) you qualify for AND list your qualifications for each category under question #5: Legal/Real Estate</i>	No
15		<b>Soil Erosion, Sedimentation and Stormwater Runoff Control Ordinance Board of Appeals (SESSRC)</b> (5 members / 3 year terms)	
16		<b>Solid Waste Council (SWC)</b> (14 members / 2 year terms) <i>Specify category(ies) you qualify for AND list your qualifications under question #5: Select One</i>	
17		<b>Veterans Affairs Administrative Committee (VA)</b> (1 member / 2 year term - must be a Veteran)	
18		<b>Workforce Development Board (WDB)</b> (2 members / 2 year terms) <i>Must apply with Agency specific application only</i>	

7. List references and contact information (minimum of two):

Reference #1

Judge Richard Allen Griffin  
United States Court of Appeals for the Sixth Circuit  
Richard\_Griffin@ca6.uscourts.gov  
(231) 929-3190

Reference #2

Megan Norris  
Chief Executive Officer, Miller Canfield Paddock and Stone  
Norris@millercanfield.com  
(313) 496-7594

8. Are you available to attend an Open Meetings Act Training Session and a Freedom of Information Act Training Session during your first year of appointment? +

Yes     No

9. Are you willing to consent to a Background Investigation?

Yes     No

10. Signature: \_\_\_\_\_



# DAVID G. KING

10275 E. Apple Ridge Dr., Traverse City, MI 49684  
231.929.3190 (o) • david.graham.king@gmail.com • 773.682.8010 (c)

## LEGAL WORK EXPERIENCE

---

**United States Court of Appeals for the Sixth Circuit**, Traverse City, Michigan  
*Career Law Clerk to The Honorable Richard Allen Griffin*, June 2015—Present

- Responsible for preparing opinions and bench memos in federal civil and criminal appeals
- Oversee day-to-day operations of Judge's chambers

**United States District Court for the Eastern District of Michigan**, Detroit, Michigan  
*Law Clerk to The Honorable Chief Judge Gerald E. Rosen*, August 2013—August 2014

- Researched and drafted numerous opinions and bench memos in both civil and criminal matters

**Miller, Canfield, Paddock and Stone, P.L.C.**, Detroit, Michigan  
*Associate*, September 2009—July 2013, September 2014—June 2015  
*Summer Associate*, Summer 2008

- Researched and drafted several legal memos, motions, and briefs in commercial and employment matters pending in trial and appellate courts (state and federal)
- Represented companies and public entities in various single plaintiff, complex, and class-action litigation
- Reviewed and revised policies for legal compliance
- Conducted workplace training on harassment and discrimination
- Negotiated and implemented collective bargaining agreements
- Spoke and wrote frequently on school law issues and on technology and social media in the workplace
- Assisted pro bono clients in obtaining veteran's disability benefits and criminal record expungements

## EDUCATION

---

**Northwestern University School of Law**, Chicago, Illinois  
*Juris Doctor, Cum Laude*, May 2009

- Honors: Dean's List Fall 2007—Spring 2009
- *Northwestern Journal of Law & Social Policy*, Executive Editor (08-09); Symposium Editor (07-08)
- Publication: Van Duyn v. Baker School District: A "Material" Improvement in Evaluating a School District's Failure to Implement Individualized Education Programs, 4 NW J.L. & Soc. Pol'y 457 (2009)

**DePaul University College of Law**, Chicago, Illinois  
*Completed First-Year Juris Doctor Curriculum*, August 2006—May 2007

- Honors: Top 5% of class, Law Review Candidate, Dean's List, CALI award for Legal Writing I

**The University of Michigan**, Ann Arbor, Michigan  
*Bachelor of Arts* in History and minor in Political Science, with *Distinction*, April 2003

- Honors: University Honors, Golden Key National Honor Society
- Activities: Resident Advisor, Honors Peer Advisor, Elementary School Tutor

## OTHER RELEVANT EXPERIENCE

---

- *Board of Directors*, The Children's House, Traverse City, Michigan (2021—Present)
- *Bar and Court Admissions*: Sixth Circuit, Eastern and Western Districts of Michigan, State Bar of Michigan (Labor and Employment and Appellate Practice Sections), Federal Bar Association
- *Judicial Extern to The Honorable Magistrate Judge Morton Denlow* (N.D. Ill.), Jan. 2009—May 2009
- *Law Clerk*, Cook County Public Guardian, Chicago, Illinois, Summer 2007
- *Research Assistant*, Professor Mark Weber, DePaul University College of Law, Summer 2007
- *AmeriCorps Volunteer*, East End Adult Education Center, Cincinnati, Ohio, 2003—2005

## INTERESTS

---

- Avid cook; Amateur triathlete and cyclist; Baseball enthusiast